In silico-aided design, build and test of synthetic proteins by Yallapragada, V. V. B.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title In silico-aided design, build and test of synthetic proteins
Author(s) Yallapragada, V. V. B.
Publication date 2019-12-20
Original citation Yallapragada, V. V. B. 2019. In silico-aided design, build and test of
synthetic proteins. PhD Thesis, University College Cork.
Type of publication Doctoral thesis








Ollscoil na Eireann, Corcaigh 
THE NATIONAL UNIVERSITY OF IRELAND, CORK 





In silico-aided design, build and test of 
synthetic proteins 
 
Thesis presented by,  
Venkata Vamsi Bharadwaj Yallapragada B.Tech, M.Sc 
under the supervision of  
Dr Mark Tangney  
 
For the degree of 
Doctor of Philosophy 
 
University College Cork 





Since the discovery of proteins in 1838, the field of protein engineering and our 
understanding of proteins have improved exponentially. Synthetic proteins have found 
applications in various biomedical, food and material-based settings. This rise in 
synthetic proteins was complemented with the parallel expansion in the availability of 
in silico tools for protein modelling. The complexity in the composition and design of 
synthetic proteins requires careful in silico validation to screen for potential pitfalls in 
the design. In silico tools for protein modelling and design have been used extensively 
to computationally validate the structure and functioning of the synthetic proteins prior 
to wet-lab testing. 
 In this thesis, the workflow of design-model-build-test of synthetic 
proteins with novel applications in imaging is described. The in silico-aided design, 
screening and the in vitro testing of synthetic proteins targeting S. aureus surface 
antigen Clumping factor A are discussed in Chapter 2. In this chapter, a suitable 
candidate worthy of examining in a future in vivo setting was identified. During the in 
silico-aided screening, the complexity of data obtained from various in silico tools 
posed new challenges. This was termed as ‘the in silico myriad problem’. In Chapter 
3, a mathematical strategy (Function2Form bridge) was tested to address the in silico 
myriad problem, by combining the scores of different design parameters pertaining to 
the synthetic protein being analysed into a single easily interpreted output describing 
overall performance. The strategy comprises 1. A mathematical strategy combining 
data from a myriad of in silico tools into an Overall Performance-score (a singular 
score informing on a user-defined overall performance); 2. The F2F-Plot, a graphical 
means of informing the wet-lab biologist holistically on designed construct suitability 
in the context of multiple parameters, highlighting scope for improvement. F2F bridge 
was implemented during the design process of all the synthetic proteins in Chapter 4 
and Chapter 5. 
 The synthetic protein design strategy used in Chapter 2 was 
implemented to design synthetic proteins targeting cancer cells, and to assess their 
potential as in vivo imaging agents in Chapter 4. For both MUC1 and ClfA targeted 
proteins, in vivo luminescence imaging studies involving systemic intravenous 
administration of proteins, validated synthetic protein specific accumulation at target 
cell locations within mice as evidenced by localised luminescence. Dose response 
iii 
 
studies indicated that luminescence output was both target cell and administered 
protein quantity related.  
 In Chapter 5, a self-assembling protein ‘cage’ was designed, built and 
tested in vitro. An accompanying novel fluorescence-based protein-protein interaction 
reporting strategy was introduced, involving incorporation of cysteine residues at the 
interaction interface of monomeric proteins of the self-assembling protein cage. In 
silico tools were used to ensure the conformational and functional stability. FlAsH 
EDT2 (fluorescin arsenical hairpin binder-ethanedithiol) mediated fluorescence was 
used to confirm the self-assembly. This demonstrates the level of accuracy and detail 
that can be incorporated into synthetic protein design using in silico tools.  
In Chapter 6, the scope of introducing miniaturised optical devices to aid 
biological experimentation was explored. A novel handheld device for monitoring 
continuous bacterial growth, with prospects of measuring biofluorescence was 
developed. The device was tested using different bacterial strains and showed 
accuracy levels similar to a standard benchtop spectrophotometer. 
This thesis demonstrates the use of computational methods and various in 
silico tools for protein design. Modern day biomedical science demands novel 
concepts with deployable technology to assist their translation into user-based settings. 
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Understanding the complexity of nature and introducing controlled modifications to 
biological systems paved the way for game-changing technology in biomedical 
sciences of the 21st century. Since the discovery of proteins in 1838, the field of protein 
engineering and our understanding of proteins have improved significantly. Synthetic 
proteins have found applications in various biomedical, food and material-based 
settings. This rise in synthetic proteins was complemented with the parallel expansion 
in the availability of in silico tools for protein modelling. The complexity in the 
composition and design of synthetic proteins requires careful in silico validation to 
screen for potential pitfalls in the design. Protein modelling, protein design and 
visualisation are the key concepts that need to be understood in this context. In this 
literature review, underlying concepts behind current protein modelling and design 
approaches are discussed.   
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1.2.1 Man’s desire to design 
“What I cannot create I do not understand”, a quote by a theoretical physicist Richard 
Feynman, accurately represents the value of ‘design’ in man’s quest for answers in 
science and also reflects a philosophical comprehension of our shortcomings in 
understanding the complexity of life. Having control over biological design and the 
ability to recreate/redesign life has been man’s dream since the dawn of genetic 
engineering [1]. The commercial and ethical barriers provided the necessary tension 
to contain the scientific creativity within its most useful uses, and this tension between 
scientific creativity and ethical scepticism has resulted in astounding results. 
Understanding the complexity of nature and introducing controlled modifications to 
biological systems paved the way for game-changing technology in biomedical 
sciences of the 21st century [2]. DNA- and protein-based developments in recent years 
have benefited heavily from the arrival of synthetic biology. The availability of large 
databases and computational tools, low-cost DNA synthesis, high-throughput testing 
systems and the parallel rise in deployment-enabling technology have contributed 
immensely towards improving the ease and pace of scientific research.  
 
1.2.2 Proteins for natural and human directed benefits 
The diversity of the functional capabilities of proteins is unmatched with any other 
class of molecules. Proteins have established themselves as the primary building 
blocks of life. Natural proteins perform and mediate many critical functions such as 
providing structure and stability, mobility, pathogen clearing and other molecular 
sensory and regulatory functions [3]. This versatility of protein function is an attribute 
of the (i) amino acid composition (ii) 3D structure and (iii) interaction with other 
proteins and various different molecules. Engineering proteins with added 
functionalities has found numerous biomedical applications. As of 2010, over 200 
protein-based therapeutics have been marketed [4, 5]. Protein-based therapies are 
being developed to target various infectious diseases and cancer , while engineered 
proteins are also extensively used in food, biotech and material technology-based 




1.2.3 Milestones and advances in our understanding of proteins 
Since the discovery of proteins in 1838 [8, 9], the field of protein engineering and our 
understanding of proteins have improved significantly. The growth in knowledge and 
products based on proteins has been complimented with the parallel rise in technology 
aiding the study of their structure and functioning. In over a century of exploration in 
protein science, the road towards complete control over protein design has been 





Figure 1.1:  Milestones and advances in our understanding of proteins. The above timeline tracks major events upto 2018.
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1.2.4 Designing synthetic proteins 
In literature, the term ‘synthetic proteins’ has been used to define various types of 
engineered proteins in various contexts. In simple terms, proteins that are produced by 
human intervention using recombinant DNA are defined as synthetic proteins. 
Synthetic proteins broadly encompass (i) recombinant proteins with added 
functionalities by fusing one or two naturally existing protein/protein fragments, (ii) 
de novo proteins that, as whole or part-wise, never existed in nature, and (iii) proteins 
with unnatural amino acids and protein-like molecules (peptidomimetics). In all these 
cases, proteins are engineered using one or more of the above-mentioned ways to 
perform a user-defined function. A user-defined function may contain multiple 
subfunctions that are associated with different structural parts of the synthetic protein.  
 For any designed protein to function as intended, it is important that the 
structure is stable, energetically feasible, and supports all the subparts in intended 
locations and conformations. Appropriate exposure of the subparts is crucial for the 
protein to perform the user-defined function at its best capability. Techniques such as 
adding small peptide tags, creating point mutations and engineering backbones are 
commonly observed in protein engineering. In certain occasions, completely novel 
peptides are generated by de novo design. Post-modification, the structure is re-
modelled, and the process is repeated until satisfactory mathematical confirmations 
are obtained. In silico aided designing stands to benefit immensely from the 
computational tools that predict protein interactions, perform backbone engineering, 
predict function and toxicity etc. [10]. The complexity in the composition and design 
of synthetic proteins requires careful in silico validation to screen for potential pitfalls 
in the design. 
 
1.2.5 Current in silico tools aiding protein design 
The rise in engineered proteins was complemented with the parallel expansion in the 
availability of in silico tools for protein modelling [10]. In silico tools for proteins 
could be broadly classified either as structure-based tools or sequence-based tools 
based on the input to the program. A majority of these computational tools help 
visualise the 3D structure of the query protein and provide graphical/mathematical 
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readout about the quality of a particular in silico parameter, such as hydrophobicity, 
active site, etc. Such an analysis and visualisation of the proteins provides deep 
insights into protein structure and forms a pivotal component in informed protein 
engineering and de novo protein design. 3D structure prediction, studying protein 
interactions and de novo design are the key aspects that need to be understood in this 
context. Figure 1.2 shows the commonly-used computational tools for protein 






Figure 1.2 Commonly used in silico tools for protein modeling and design 
  
Figure 1: In silico tools for protein modelling and design. 
10 
 
1.2.5.1 Understanding protein folding 
Elucidating the structure of proteins revolutionized the field of protein science and 
paved the way for establishment of massive databases. Traditionally, physical methods 
such as NMR spectroscopy and X-Ray crystallography are deployed to elucidate and 
study the 3D structure of proteins. The recent advances in computational sciences have 
resulted in sophisticated algorithms for predicting and modelling the 3D structure of a 
protein from its corresponding amino acid sequence. The concepts of protein fold 
prediction revolve around free energy models, stereochemistry and nature directed 
homology [11]. The degree of freedom in a conformation (steric and torsional effects), 
chemical interactions with neighbouring residues and physical forces surrounding the 
residues are the main elements that dictate protein folding [12, 13]. Properties such as 
charge, polarity and hydrophobicity of the residues also have significant influence on 
the final structure. This enormous number of variables and the combinatorial 
explosion of the feasible conformations make the protein-folding problem highly 
complicated. 
 
1.2.5.1.1 Protein modelling algorithms for finding the energy minima(s) of a 
protein 
American biochemist Christian Anfinsen, in his thermodynamic hypothesis, known as 
Anfinsen’s dogma, proposed that “in the right physiological conditions, a protein will 
always fold into its native state”. This native state of a protein is defined as the lowest 
Gibbs-free energy state that can be achieved by its amino acid sequence. This 
argument was backed-up by physical structure determination techniques such as X-
ray crystallography, which soon was adopted as a standard method for protein 
structure determination. Crystallography, however, forces proteins into a single 
diffractible crystal and thus may exhibit only one native structure [14]. This ‘one 
protein – one structure’ supposition was later challenged through the discovery of 
‘chameleonic’ sequences, metamorphic proteins and intrinsically disordered proteins 
[14]. The free energy landscape of a protein has multiple local minima in which a 
protein can settle. This presence of multiple local minima poses the greatest challenge 
in computational protein structure prediction. Over the years, various mathematical 
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strategies were proposed to provide a solution to the free energy landscape problem. 
Figure 1.3 illustrates the free energy landscape of a protein. Table 1.1 details the 
modelling algorithms commonly used in various protein structure prediction tools. 
Understanding the merits and demerits of the type of modelling algorithm used is 






Figure 1.3: Free energy landscape of a protein. The energy landscape of a protein 
has multiple mimima. The first minimum from the starting set of atomic positions is 





Gradient based minimization 
Proceeds in the direction in which free 
energy decreases rapidly.  
Finds the nearest local minimum 
effectively  
Fails to generate global minimum 
Monte Carlo based sampling 
Proceeds by random sampling by 
accepting/rejecting moves based on free 
energy 
Finds global minimum effectively 
Molecular dynamic simulations 
Uses Newton’s laws of motion and 
calculates the force acting on each atom, due 
to surrounding atoms in the protein and 
environment. Alternative to Monte Carlo 
sampling. 
Highly time consuming and requires high 
computational power 
Table 1.1: Commonly used modelling algorithms for protein structure prediction. 




1.2.5.2 Protein structure prediction 
The protein folding problem was historically solved with appreciable accuracy using 
two strategies: i. Ab initio methods, and ii. Homology-based methods [15]. 
 
1.2.5.2.1 Ab initio methods (Template-free method) 
Ab initio refers to first principle methods. Tools that rely on ab initio methods for 
predicting use laws of physics and do not rely on protein databases [4]. Ab initio 
methods simulate the conformations using free energy function to describe the internal 
free energy of a protein structure and the interactions of the 3D structure with the 
surrounding environment. The ultimate goal of the strategy is to seek the conformation 
with the lowest free energy, that corresponds to the functional state of the protein. [11]. 
 
1.2.5.2.2 Homology-based methods (Template-based method) 
In this method, the secondary structure of a protein is obtained by comparing the 
fragments with sequence homology in existing protein databases [11]. The accuracy 
of prediction depends on the availability of homologous sequences in the databases. 
Therefore, most naturally existing proteins could be modelled using homology 
modelling with high accuracy. However, while predicting the structure of synthetic 
proteins, the confidence in predicted structure depends on how close the synthetic 
protein resembles the naturally existing proteins.  
Today's modelling uses a combination of both homology-based and ab initio methods 
to elucidate the 3D structure. Once the query sequence is given as an input, sequence 
alignment tools perform a thorough analysis to find similarities in the databases. In 
most cases, the similarities occur in small fragments all through the sequence. 
Computational tools are used to model the homologous parts using the proteins in the 
Protein Database (PDB) as a template. The sections of the sequence with minimal or 
no similarity are subjected to ab initio methods. Such an approach provides an optimal 
result in most cases. This process gives a linear chain of secondary structure fragments. 
Once the whole sequence has been modelled, the fragments are assembled by 
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threading, and refined to rank the predicted conformations based on free energy 




Figure 1.4: Protein structure prediction methods. Sequence of events in ab initio and template-based modelling methods.  
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Computational tools for protein modelling and protein interaction studies 
3D structure prediction tools (based on popularity and CASP) 
I-Tasser [16]  • Iterative Threading ASSEmbly Refinement developed by 
Zhang Lab: Uses fold recognition (threading) and Ab initio 
methods to detect structure templates from existing 
databases (PDB). 3D models of the query sequence are 
constructed by reassembling structural fragments by replica 




Modeller [17] Template based homology modelling program developed by 
Andrej Sali (University of California, San Francisco, 
Accelrys). Uses Ab initio structure prediction for regions 
with high variability. 
https://salilab.or
g/modeller/ 
Rosetta Automated protein structure prediction server developed by 





• Raptor X [18] • Developed by Xu group, Raptor X uses remote homology 
recognition/protein threading for structure prediction. 
Provided best alignments for difficult targets in CASP 9.  
• http://raptorx.uc
hicago.edu/ 
Tools for studying protein interactions (based on popularity and CAPRI) 
ClusPro [19] • Widely used tool for protein-protein docking, developed by 
S Vajda et al (ABC Group and Structural Bioinformatics 
Lab Boston University and Stony Brook University). 
ClusPro also has an antibody mode. Uses PIPER (FFT 




• Z Dock [20] • Developed by Weng Z et al (University of Massachusetts 
Medical School and Boston University), predicts structures 
of protein-protein complexes and symmetrical multimers. 
Performs rigid body search for docking interaction between 
two proteins and uses FFT to find possible binding modes 





• Uses particle swarm optimization to find low energy 
positions and binding orientations. Works in both full blind 
and restrained modes depending upon the availability of the 








• Developed at Arthur J. Olson's Laboratory (The Scripps 
Research Institute and University of California). Widely 
known for receptor-ligand docking but also could be used 
for protein-protein docking. 
http://autodock.s
cripps.edu/ 





1.2.5.3 De novo design and structural remodelling 
Having partial predictive control on the protein function and redefining the functions 
have driven the field of protein engineering into an era of unprecedented development. 
However, the total number of existing proteins in nature is finite and the combinations 
using recombinant engineering also has limitations on what can be achieved. Nature 
has sampled only a fraction of total possible combinations in the total sequence space 
[13]. For example, a typical 100 amino acid protein can have about 20100 different 
sequence variations. Given the multiple sizes of each protein, the number of total 
possible proteins is beyond magnitudes of human interpretation. Nature on the other 
hand has a little over 1012 different proteins. This huge gap forms the drawing canvas 






Figure 1.5: Protein sequence space representation. Natural proteins occupy a minute 
fraction of the total sequence space. Directed evolution and recombinant technology 
in recent years have stretched the used sequence space. De novo protein design stands 





De novo protein design breaks the evolutionary constraints placed by nature and 
explores all the mathematically feasible structures in the protein canvas. In theory, de 
novo design is the opposite of protein modelling. Protein modelling asks the question 
of whether it is possible to predict the protein structure of a given amino acid sequence. 
While the de novo design on the other hand, asks whether it is possible to determine 
an amino acid sequence that would fold into a specified query structure [4] (Figure 
1.6).  
Despite the immense potential of rational de novo protein design, more than 95% of 
protein engineering is still being carried out by inserting random mutations and 
selecting those which confer an advantage [23]. The rational design of proteins falls 
into two categories - the redesign of existing proteins in a process analogous to 
directed evolution, and the de novo design of completely novel proteins. Protein 
redesign uses naturally occurring proteins as scaffolds, and then engineers them to 
introduce desired changes, such as increased stability or new functional properties 
[24]. This will produce novel proteins, but their origins will be firmly based in the 
naturally occurring protein fold space. The majority of protein engineering to date has 
been of this nature. This method is convenient as it provides a protein backbone 
starting block, particularly if the desired effect represents a minor alteration in the 
protein’s function. This becomes complicated when large numbers of amino acids are 
altered, since it becomes inevitable that the structure will also be altered. Native 
proteins are only marginally stable in many cases, so even small sequence changes can 
lead to dramatic changes such as aggregation or unfolding [25]. Major advances in 
medical science directly resulting from this degree of protein design include the 
humanisation of antibodies from other animal species, which entails modifying the 
wild type antibody to resemble human antibodies while retaining the original function. 
Two examples are Alemtuzumab [26] and Mepozulimab [27] for the treatment of 
multiple sclerosis and eosinophilic asthma respectively.  
True de novo protein design explores the entirety of protein sequence space, guided 
only by the physical interactions that control protein folding. The scale of possible 
proteins, once naturally occurring proteins are left behind, is enormous. De novo 
protein design is based on the hypothesis that a protein will always fold into the shape 
associated with the lowest free energy state allowable by the amino acid sequence. 
Therefore, if an accurate method for measuring the energy of protein chains is 
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available, in addition to a method to sample different structures and sequences, it 
should be possible to identify sequences that fold into novel structures [25]. Once the 
desired shape has been reached, the stability of the novel protein can be improved by 
making minor adjustments, maximising the difference in free energy between the 
desired conformation and alternatives. De novo design brings the possibility of 
producing protein structures with novel functions that never existed in nature. Various 
researchers have utilised de novo design concepts to produce an array of repeat 
proteins, symmetry aided design of self-assembly and designing interfaces with 
special affinity towards a target [28]. However, the de novo design process relies 
entirely on computational simulations. This can hinder the accuracy of the predictions 





Figure 1.6: Difference between protein modelling and design. Protein design can be 
understood as the inverse of protein modeling. In protein design, computational 




The principles of de novo design could also be used for structural remodelling. In 
protein engineering, structural modelling is performed when a small region on a 
protein structure requires a modification. Deleting certain residues, reconstructing 
backbones, disarming functional regions etc., require changes in amino acids without 
causing significant changes to the original protein structure. In such cases, de novo 
design principles are used for structural remodelling. 
 
1.2.5.4 Predicting protein-protein interactions 
Proteins perform and mediate various life functions by their interactions. Predicting 
protein interactions is crucial to understand protein function. Acquiring atomic level 
information of protein interactions from a wet lab study is extremely difficult to 
achieve. Thus, predicting protein interactions computationally is gaining popularity. 
Predicting protein interactions is a challenge, even using sophisticated computational 
algorithms. The range of potential interactions with the surroundings (medium), 
structural rearrangement associated with binding, flexibility, time scale and other 
physical factors are some of the well-known hurdles. In computational terminology, 
inter-molecule binding interaction is termed as docking. Docking is widely used 
method to study interactions of small molecules. The motion of the molecules post-
interaction and structural changes while binding, are not considered. Thus, the rigid 
body docking falls out of agreement with large proteins. Tools such as RosettaDock 
have used Monte Carlo minimization-based methods to implement semi-flexible 
docking, specifically for proteins [29]. However, a universally reliable docking tool 
for full chain protein-protein interaction is a topic under research. Commonly used 
computational tools for studying protein interactions are listed in Table 1.2. 
1.2.5.5 Visualisation tools aiding protein design 
Visualisation of the 3D structure of a protein is an important component in both 
modelling protein structure (Physical methods and/or computational prediction) and 
protein design. Visualisation (i) For biochemists: Provides insights into various 
protein domains such as hydrophobic regions, active sites and catalytic sites. (ii) For 
evolutionary biologists: Visualising and mapping 3D structures aids in studying 
homology in structure. (iii) In drug designing: Visualising protein-protein 
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interactions and protein interactions with small-molecules is key to understand 
binding. (iv) In de novo protein design: Visualizing the designed backbone structures 
and superimposing the designed structures with experimental structures are very 






Figure 1.7: Applications of molecular visualisation. Interior graphics: Connection 




1.2.6.1 Current tools for visualising proteins 
The early 20th century saw a sudden increase in the number of protein structures 
deposited in protein databases [30] and thus a need for better visualisation tools 
increased in parallel. Over the years, a wide variety of visualisation tools have been 
developed and deployed for protein structure visualisation. Pymol [31], VMD [32], 
Chimera [33] and Rasmol [34] are some examples of widely used standalone 
applications. Later, web-based applications such as Jmol [35] and iView [36] gained 
interest in the scientific community. Recently, several mobile-based applications for 
android and iOS have also been developed by various groups for molecular 
visualisation. Visualising biomolecules (proteins in particular) in virtual reality has 
gained wide attention recently [37]. Tools such as ChimeraX [38], BioVR [39], 
StarCave [40] (cave based) have been developed for visualising the 3D structure of 
proteins in virtual reality. Although the current technology provides a plethora of 
functionalities for the user, the potential of molecular visualisation in VR is still a 
maturing field. Easier navigation in the VR environment, better UI (user interface), 
faster rendering, and simplified instrumentation are some areas that are expected to 
see some improvements in the near future. Parallel advances in affordable VR 
headsets, increasing computational power and graphics, project interesting times 
ahead. 
1.2.7 Commercial landscape of protein design technology 
The protein engineering market value is estimated to reach $3.9 billion by 2024 at a 
CAGR of 12.4% [41]. Biotech industries and Big Pharma have successfully taken the 
commercial advantage of the ‘build’, ‘test’ and ‘production’ phases of the protein 
production chain. By expanding the protein canvas, de novo design opened an 
enormous opportunity for business. As a consequence, the in silico design and 
modeling phase gained new commercial interests. Although the ‘build’ and ‘product’ 
phases still remain as the major money generating stages, the recent surge of start-ups 
focusing on the design phase is an early indicator of the in silico revolution. Figure 
1.8 shows various phases of the protein production chain.  
Table 1.3 details the services, technology used and information on the commercial 
stage of recent companies focusing on the ‘design and modelling’ phase of protein 
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production chain. The association of these protein design companies and their parent 
institutions with Big Pharma and biotech industries indicates that designer synthetic 






Figure 1.8: Various phases of protein production chain and commercial entities at 
each phase. Top: Technologies and services involved in the protein production chain. 
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sequence-function relationships based on 
experimental data. 
MOSAIC: Evaluates the interactions of 
multiple mutations 
• Machine learning 
• Neural networks 




Post IPO Equity 
 
Lead Investor 







• Protein engineering 
• Scale-up and Supply 









De Novo Protein Design 
Custom de novo designed proteins for 
therapeutic applications 
The Neoleukin Platform 
Proving protein modification, de novo 















• Protein structure determination 
• Protein design and 
• Protein property optimisation services 
• Quantum computing 
• Molecular dynamic 
simulations 
• Artificial intelligence 
and  















• Antibody Design and Optimization 
• Protein Developability Assessment 
• Automated Thermostability Engineering 




• non-linear modeling 
• statistical approaches 
• progressive AI 











Oral enzyme for 
Celiac disease 
KUMAMAX – an oral enzyme for the 


















Offers service and 
solutions for 








• Protein design 
• Protein structure prediction 
NMR and X-Ray crystallography 
Cyrus Bench: Rosetta 
based suite for molecular 
modeling and design 
 
Cyrus Bench is an easy-
to-use version of various 
Rosetta based tools packed 

















Protein based therapeutics 
• Improved targeting 
• Adding custom properties 
• Exploring potential drug candidates 
 
• EVA- machine learning-
driven evolution engine. 
• Deep-learning neural 




Early stage venture 
Privately-owned company 






Table 1: Services, technology used and the commercial stage of recent companies focusing on the ‘design and modelling’ phase of 
protein production chain 
*Information on commercial stage, lead investors, estimated revenue and investment amounts was obtained from Crunchbase [52].
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1.2.8 How far are we from designer proteins 
1.2.8.1 Costs of protein production and testing  
The advent of synthetic biology has brought down the costs associated with DNA 
sequencing and analysis dramatically [53,54]. This had a profound effect in lowering 
research costs which involve studying DNA and technology and products that depend on 
synthetic DNA. Miniaturised and portable devices for sequencing, handheld alternatives 
for PCRs, spectrophotometers have enabled the deployment of DNA based technology 
into commercial settings [55-57]. Protein based technology, on the other hand, is playing 
a catching-up game, the reliance on large bench top instrumentation such as NMR, X-Ray 
crystallography, Cryo-EM based methods and traditional testing methods involving 
expensive reagents such as antibodies and a lack of robust and affordable in vitro testing 
systems are some hurdles to overcome in coming future. 
1.2.8.2 Reliability of in silico tools 
The reliability of outputs of the current in silico tools for protein modelling and design 
depends on several factors, such as protein complexity, sequence and structural homology 
and the choice of individual algorithms and methods used in the in silico workflow. 
However, on a global scale, community-wide experiments such as Critical Assessment 
of protein Structure Prediction (CASP), Critical Assessment of PRediction of Interactions 
(CAPRI) and the Critical Assessment of Functional Annotation (CAFA) have been 
benchmarking the computational tools for structure prediction, protein interaction 
prediction and function prediction. This is achieved by ranking the in silico tools based 
on their blind-folded prediction ability of various sets of queries. CASP, CAPRI and 
CAFA are conducted once every two years. The improvement in the performance shown 




1.2.8.3 Deploying synthetic proteins 
The applications of synthetic proteins expand into various sectors such as food-based 
industries, materials technology, and biomedicine. The advent of de novo protein design 
has only increased the ever-expanding canvas of protein structures. The advances in 
synthetic biology are promoting lab-based novel scientific concepts to translate into 
deployable and commercially-viable products. Commercial viability requires 
transforming a scientific outcome into a deployable product. For example, a protein based 
diagnostic tool would additionally require an appropriate hardware for testing and a 
software to analyse and report the results. The deployability factor becomes crucial while 
these lab-based concepts shift to commercial or consumer-based settings. 
Interdisciplinary approaches form a bridge connecting a scientific concept and a 
consumer.  
1.2.8.4 Regulations and ethics  
Use of purified engineered proteins presents lower environmental, food and drug 
regulatory barriers than ‘live’ products featuring genetically engineered DNA, given a 
typical protein’s ‘terminal’ state. Nonetheless, immunotherapy with engineered 
antibodies, CAR-T cell technology, Crisper-Cas9, protein-based drugs for autoimmune 
diseases and Gene Therapy have multiple forms of protein engineering as a key integral 
component and have always been a topic in scientific ethics and policy making [58-60]. 
Having control over biological design and the ability to recreate/redesign life has been 
man’s dream since the dawn of genetic engineering [1]. Commercial and ethical barriers 
provided the necessary tension to contain the scientific creativity within its most useful 
uses, and this tension between scientific creativity and ethical scepticism is producing a 






Our ability to design and engineer proteins has advanced considerably over the last 
decade. In this review, various in silico tools that are crucial for synthetic protein design 
have been highlighted. Special focus was placed on (i) protein structure prediction, (ii) de 
novo protein design and (iii) protein visualisation techniques, all of which are studied in 
this thesis. The value of integrating multidisciplinary approaches in transforming a 
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Background  Incorporation of minimal regions of antibodies within engineered proteins 
presents an attractive strategy to target proteins to specific molecules or cells. Such 
targeted synthetic proteins have an enormous potential in various diagnostic and 
therapeutic applications. Designing a synthetic protein involves modeling and testing 
multiple test variants. A typical synthetic protein with 5 defined subparts can be 
assembled into 5! i.e. 120 different variants. Current in silico tools help identify merits 
and pitfalls of the design and aid in screening for potential best performers. Such an in 
silico aided screening reduces the costs and labour involved in wet-lab experimentation. 
Aims  The aim of this work was to (i) computationally design and model multiple 
variants of a bacterial targeted synthetic protein and screen for potential best performers, 
and (ii) build and test the synthetic protein test variants using wet-lab assays. 
Methods  Over 50 different multi-part test constructs targeted to S. aureus surface 
antigen ClfA were modelled and validated using various computational tools to inform 
and guide downstream wet-lab experiments. For targeting, constructs featured either 
mono-valent ScFVs or bi-valent mono-specific diabody fragment sequences. Gaussia 
luciferase (Gluc) was used as a luminescence reporter on all test variants. All test construct 
variants were subjected to computational screening of predicted functionality. The best 
predicted performers were appropriately modified to ensure required hydrophobicity, net 
surface charge, active site exposure and valid 3D structure. After a thorough in silico 
validation, wet-lab studies were conducted to validate protein production and functioning 
(lumiescence and specific target binding) in vitro.  
Results  Following in silico design and analyses, 10 test constructs against ClfA 
were produced in CHO cells and tested for specific target binding in vitro. Based on 
luminescence readouts, a ScFv-featuring test construct was identified as the best 
performer, in terms of S. aureus specific binding, as evidenced by luminescence-based 
assays.  
Conclusion  The outputs of this study were i) a validated in silico and wet-lab strategy 
for design, build and test of targeting synthetic proteins, and ii) a target-specific reporter 





2.2.1 Synthetic proteins with minimal regions of antibodies 
Over the last decade, the number of protein-based imaging and therapeutic applications 
have grown considerably. Engineering proteins to target specific cells or proteins is a 
common approach used in protein-based biomedical applications [1]. This targeting 
requires the binding of proteins to targets of interest. Using antibodies as targeting leads 
is a well-known strategy. Radioactive labeling of antibodies and chemical conjugations 
with fluorescent labels and nanoparticles are some of the common ways of exploiting 
antibodies. However, due to the large size, full antibodies present many disadvantages 
such as risk of immunogenicity, slow clearance and low tissue penetration [2-4]. 
 Incorporating minimal antibody regions into a synthetic protein as a 
binding domain is an attractive strategy for targeting a subject of interest. The small size 
of the minimal regions improves the pharmacokinetic properties and reduces the risk of 
immunogenicity. A typical synthetic protein consists of multiple subparts with individual 
functions. The small size of the minimal regions provides great flexibility in design. 
Depending on the user requirement, the minimal regions can be assembled into multiple 
variants of antibody fragments such as ScFvs, diabodies, nanobodies etc. The valency and 
specificity of the synthetic protein could be altered by using multiple minimal regions of 
antibodies with different targets. Figure 2.1 illustrates a few examples of antibody 
fragments constructed from the minimal regions of a full IgG antibody. 
 The functional versatility of proteins and modular aspects of recombinant 
protein engineering paved the way towards designing proteins with multiple added 
functionalities. In the last decade, engineering antibodies for customised applications took 
an unprecedented development [5]. Engineered antibody fragments are fragmented small 
antibody parts assembled by researchers for diversifying and improving the functionality. 
With current computational tools and engineering of appropriate genetic elements, 
antibodies could be engineered to have customised affinity, half-life, valency, minimal 
toxicity, avidity and other specific biological functions [5, 6]. Examples of such 





Figure 2.1: Original IgG antibody format and various engineered antibody fragments. 
The engineered antibody fragments differ in their specificity, stability and valency. VH 
and VL domains are the minimal regions of the antibody that primarily contribute to 
binding to the target. The presence of multiple copies of minimal regions increases the 
valency of the antibody fragment and the presence of minimal regions from two or more 
different antibodies adds multiple target specificity (shown in different colors). The 





2.2.2 Designing a synthetic protein with multiple ‘parts’ 
Designing a synthetic protein with a defined function requires building and testing of a 
range of variants. For any designed protein to function as intended, it is important that the 
structure is stable, energetically feasible, and supports all the subparts in the intended 
locations and conformations. In most cases, the synthetic protein is composed of smaller 
subparts with unique subfunctions. These parts are connected to each other directly or by 
using small peptide linkers. The subparts may also include additional enhancer elements 
to improve the stability, solubility and secretion as appropriate. As the number of subparts 
increases, the choice of subpart types, variants and the number of ways to assemble these 





Figure 2.2: Number of variants possible for a synthetic protein with 4 subparts. For a 
protein with 4 subparts where there are n different choices available for a secretion 
signal, m different choices for the linkers, o different choices for the solubility enhancer 
and p different choices for the detection tag. In most cases the order of the assembly also 




For 4 subpart construct, with each subpart belonging to a subset (n,m,o,p), the total 
possible variants are given in the formula below.  
[𝑛 + 𝑚 + 𝑜 + 𝑝]!/[(𝑛 + 𝑚 + 𝑜 + 𝑝) − 4]!  
For an R subparts construct, the equation changes to: 
[𝑛 + 𝑚 + 𝑜 + 𝑝+. . . . . . . ]!/[(𝑛 + 𝑚 + 𝑜 + 𝑝+. . . . . ) − 𝑅]!  
Wet lab synthesis and testing of all variants is a laborious and highly expensive process. 
Such methods are also not suitable for high throughput applications. Computationally 
modeling the test variants and in silico screening provides a screening rationale and also 
assists the wet-lab biologist by informing about the pitfalls and merits of an engineered 
protein, prior to synthesis. The final design variants can also be improved continuously 
based on the feedback from the computational tools.  
2.2.3 Bacterial Imaging 
Bacteria present both a beneficial and a detrimental role for various human needs. 
Understanding the pathogenicity of bacteria is crucial clinically, in preventing and curing 
infectious diseases. For research purposes, monitoring bacterial trafficking in the body is 
valuable. Non-invasive detection of specific bacteria also benefits diagnosis and treatment 
of infectious diseases. Developing a non-invasive imaging strategy to detect bacteria 
within a living host would benefit various fields including, infectious diseases, gene 
therapy and cancer.   
2.2.4 Staphylococcus aureus 
S. aureus is a Gram-positive, clinically important pathogen that can cause a range of 
diseases from superficial skin infections to pneumonia, endocarditis and fatal sepsis in 
humans [7]. S. aureus is often found in skin and nostrils and is a formidable opportunistic 
type. The ability of S. aureus to survive in a variety of locations in the body is an attribute 
of its range of virulence factors such as toxins, adhesins and proteins that help it to evade 
the immune system [8, 9]. Understanding the mechanism of S. aureus interactions with 
the host provides insights to develop novel imaging and therapeutic strategies. Biofilm 
formation and aggregation or microcolony establishment are the two main modes of S. 
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aureus infections [10]. Biofilm based S. aureus infections are common in medical devices 
and other surface-based settings [11]. However, microcolony establishments are 
increasingly seen in host infections. In microcolony based infections, S. aureus aggregates 
are embedded into the extracellular matrix composed of proteins such as fibrinogen and 
collagen [10]. S. aureus also interacts directly with fibrinogen and thus forms large 






Figure 2.3: Crystal structure of human fibrinogen (PDB ID: 3GHG). The 𝛼, 𝝱 and 𝜸 
chains are depicted in red, green and blue respectively. The MSCRAMM, microbial 
surface component recognizing adhesive matrix molecules binding site is highlighted in 




This ability to interact with fibrinogen is a hallmark feature of S. aureus and is known as 
clumping (Figure 2.4). The clumping of S. aureus is facilitated by its virulence factor 
ClfA (Clumping factor A) [12]. Targeting the virulence factor ClfA (clumping factor A) 






Figure 2.4: Schematic showing clumping of S. aureus. ClfA facilitates clumping by 
binding to distal ends of fibrinogen dimer. This allows the dimer to act as a connecting 




2.2.5 Gaussia Luciferase as a reporter protein 
Bioluminescence is the liberation of energy in the form of light by a reporter protein 
which, in most cases, oxidises a substrate molecule in an ATP (or FMNH2) dependent 
manner [13]. Bioluminescence reactions do not require light absorption/excitation. 
Bioluminescence depends on an enzyme called luciferase, a substrate, commonly known 
as luciferin and oxygen. Some reactions also would require, ATP and Mg2+ as cofactors 
for their activity. The term luciferase encompasses all the enzymes that produce light on 
catalysis. There are a wide variety of luciferases found in nature ranging from fireflies to 
deep ocean algae. Firefly (Fluc), Click Beetle (CBluc), Renilla (Rluc) and Gaussia (Gluc) 
are a few of the most widely studied luciferases [14-16]. Amongst all the luciferases 
mentioned above, Gluc is an ATP independent luciferase. The working mechanism of 
Gluc is shown in figure 2.5. Due to its small size, ATP independent working, high stability 
at elevated temperatures, ability to be secreted outside the cells and bright signal, Gluc is 





Figure 2.5: Working mechanism of Gaussia luciferase catalysed bioluminescence. 
Gaussia luciferase catalyses the conversion of its substrate Coelenterazine to 
coelenteramide, in presence of oxygen. During this process energy is emitted in the form 




The potential of bioluminescence imaging has been explored previously in various disease 
settings. Bioluminescence has been previously used to study mRNA stability, miRNA 
expression, studying signaling pathways, post translational modifications, protein-protein 
interactions, understanding kinetics of proteins, imaging tumors, etc [17]. 
Bioluminescence represents an efficient and affordable method, as the instrumentation 
required is relatively inexpensive, low-cost and minimal consumables are required, 
minimal technical expertise is required to learn the imaging methodology and easy data 
analysis [18]. Considering the above-mentioned advantages, bioluminescence based 
Optical Imaging promises a huge potential to be deployed as a novel imaging strategy 
towards various fields of medicine.  
 
This study demonstrates the proof-of-concept of the design-model-build-test strategy of 




2.3 MATERIALS AND METHODS 
2.3.1 Overview of in silico design of synthetic proteins 
Synthetic proteins contained multiple subparts with individual subfunctions. Over 200 
different variants were made and manually screened for potential best performers. Various 
in silico tools were used during this process and several iterations of each test variant were 
validated until desired structural conformations were achieved. VH and VL domains of 
anti ClfA antibody MAb 12-9 was used as the binding domain to target ClfA on S. aureus. 
The amino acid sequence was obtained from a patent application. 
http://www.google.ch/patents/US20050287164  
Gluc was used as the luminescent imaging part. The test variants differed in their part 
arrangement order, presence and absence of additional domains. The process workflow 
and methods are explained in the sections below. 
2.3.2 Computational tools used for in silico -aided design and validation 
2.3.2.1 Protein structure modeling 
All the amino acid sequences of the test variants were subjected to protein modeling to 
predict their 3D conformation. The protein modeling was performed primarily using the 
I-Tasser protein modeling suite [19]. Both web server and the standalone suite were used 
to perform modeling of multiple constructs in parallel. C-score from the I-Tasser output 
was used to determine the best model after each modeling experiment. Higher C-Score 
indicates higher confidence in the predicted model. The test constructs were also modeled 
using Rosetta modeling suite to increase the prediction reliability [20, 21].  
2.3.2.2 Superimposing predicted models 
The models predicted by I-Tasser and Rosetta were superimposed onto each other to 
calculate the agreement of the relative position of each atom in space. Root Mean Square 
Distance (RMSD) was used as parameter to judge the agreement between the models 
predicted by the two modeling tools. R-algorithms, developed in-house at the Tangney 
lab, were used for this purpose. 
56 
 
2.3.2.3 3D visualisation 
Visualising protein structures in 3D is a central element of protein modeling. The 
alignment of important parts in right conformation was ensured by visually validating 
each individual test variant. UCSF Chimera was used for all protein visualisation 
throughout this work [22]. Highlighting various domains and specific sequences in the 
3D structure, hydrophobicity and polarity depiction were all carried out using the internal 
options in Chimera. Chimera was also used to visualise protein-protein interactions after 
protein docking which was carried in the later stages of this workflow.   
2.3.2.4 Protein-protein interactions 
Protein-protein interactions were studied using protein docking. AutoDock Vina was used 
for protein docking [23]. Free energy change (ΔG) was used as an indicator for judging 
the quality of interactions. The negative sign indicates the energy released during the 
interaction. Higher numerical values of ΔG reflect stronger interactions. All the bound 
conformations were visualised in UCSF Chimera to screen for conformations that bind at 
the active sites (epitope-paratope interaction).  
2.3.2.5 Theoretical structure validation 
Ramachandran plots (RC plots) were used to validate the theoretical stability of the 
modeled structures. RC plots inform the percentages of residues that occur in the 
theoretically favored, allowed and disallowed regions. This information could be used to 
verify the structural stability of the model to exist in a natural environment. 
2.3.2.6 Total hydrophobicity vs Surface hydrophobicity 
Hydrophobicity of the 3D models explains the integrity of the conformation in a water 
based medium. Large sections of hydrophobic residues on the surface of the structure 
result in structural deformation when dissolved in an aqueous medium. Regular 
hydrophobicity calculators inform the summative hydrophobicity of the entire protein. 
However, the hydrophobic residues deprived of external exposure do not contribute to the 
instability. Surface hydrophobicity was mathematically calculated by identifying the 
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residues which have over 40 % exposure. The hydrophobicity is then calculated for these 
surface residues using in-house R algorithms. 
2.3.2.7 Structural remodeling and affinity improvements 
Improvements to the backbones, linkers and single residue replacements required 
structural remodeling. This was performed using Rosetta package. In cases where the 
modification is very small, the specific region is remodeled instead of modeling the whole 
structure. 
2.3.3 DNA design  
Following the in silico validation of all the test sequence. The finalised constructs were 
reverse translated into their corresponding DNA sequences using backtranseq feature on 
EBI website (https://www.ebi.ac.uk/Tools/st/emboss_backtranseq/). The DNA sequences 
were codon optimised for CHO cells using the codon optimisation tool available on IDT 
website (https://eu.idtdna.com/codonopt). The final constructs were obtained from Twist 
Bioscience company. Due to fragment size restriction on DNA synthesis, some of the 
constructs were synthesised in multiple parts. NEB and SnapGene’s Gibson assembly 
simulators were used to design the homologous arms to facilitate Gibson assembly. 
Amplification and sequencing primers were designed using Benchling’s primer design 
tool. The primers were cross verified using Primer3Plus. All primers were sourced from 





Primer name Sequence 
FullSeqFWd AATTCAAAGGAGGTACCCACCA  
FullSeqREV AGGTAGATATCGCGGTACCCTTA 
StaphDia1aREV GTG ATA CTA AGG CTT TGA GAA GGT 
StaphDia1bFWD  TCT CAA AGC CTT AGT ATC ACT TGT GC 
StaphDia3aREV CAA GCG AGG TAG TTC TTT TGA 
StaphDia3bFWD CAA AAG AAC TAC CTC GCT TGG 
StaphDia4aREV  TTT TGT TGA TAC CAT GCC AAA T 
StaphDia4bFWD TTG GCA TGG TAT CAA CAA AAG 
StaphDia5aREV  GAG TTC ATC TTC AAA AAG ACC TGT G 
StaphDia5bFWD GTC TTT TTG AAG ATG AAC TCT CTG C 




2.3.4 Plasmid scale-up 
OG176 plasmid (Oxford genetics) with Kanamycin resistance was chosen for producing 
the synthetic proteins. E. coli BL21 cells were used for plasmid scale-up. E. coli BL21 
Cells were made competent using Cohen et al. 1972 protocol. 100 ng OG176 was mixed 
with 30 µl competent E. coli BL21 cells and were placed on ice for 20 min. The suspension 
was subjected to heat shock at 42◦Cfor 20 min. The cells were again placed on ice for 2 
min and 1 ml of LB broth was added. 100 µl of the transformed cells were plated on LB 
agar containing 50 µg/ml Kanamycin. The colonies were then subcultured and stored in -
80 ◦Cfor further use. For plasmid extraction, overnight subcultures of the transformed 
bacteria are subjected through Monarch Plasmid miniprep kit (New England Biolabs) 
protocol.  
2.3.5 Restriction digestion 
OG176 was digested by restriction enzyme Nco1 HiFI with CutSmart reaction buffer 
(NEB) at 37 ◦C for 1 h. Manufacturer’s protocol was followed to adjust the reaction 
volumes as per the need. Following the restriction digest, the DNA was purified using 
PCR purification kit (Qiagen) protocol. In all cases, the restriction digest was verified by 
Agarose gel electrophoresis and the DNA concentration was determined using a 
NanoDrop spectrophotometer (Thermofisher). 
2.3.6 Gibson Assembly 
Gibson Assembly was carried out using the Gibson Assembly master mix described by 
DG Gibson et al (2009). The plasmid and DNA gene blocks were mixed in 1:3 ratio in a 
Gibson Assembly master mix and incubated at 50 ◦C. E. coli BL21 cells were transformed 
with the assembled plasmids and plated on LB agar medium.  
2.3.7 Validating cloning using colony PCR and Sanger sequencing 
The selected colonies were added to NEB PCR master mix with 2.5 µl of corresponding 
primers. PCR was carried out as per NEB Q5 polymerase PCR protocol. Sanger 
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sequencing (GATC light-run) was also performed on the selected colonies to confirm the 
assembly. 
2.3.8 In vitro transfection 
CHO K1 cells were transfected using Turbofect transfection reagent (Thermofisher). 
Manufacturer's protocol was used to perform transfection. Supernatant from the cells were 
collected at 24 h and 48 h intervals. 
2.3.9 Binding assays  
S. aureus TCH959 (naturally bearing ClfA) cells (108 cells per sample) were blocked with 
5 % BSA for 2 h followed by incubation with supernatant containing each test construct. 
Cells were washed 3 times and resuspended in PBS. 10 µl of each sample is taken in 
triplicates into a corning 96 well white plate. 50 µl of Coelenterazine substrate was added 




2.4.1 Design elements and design rationale 
Targeted luminescence is the overall function of these synthetic proteins. Several test 
variations of the synthetic proteins were made during the design phase. Heavy and light 
chains of anti-ClfA antibody MAb 12-9, were used as the binding site (T-domain). A 
monospecific monovalent monobody (single chain variable fragment (ScFv)) and a 
monospecific bivalent diabody versions were chosen as the binding site variants. The 
choice of subparts and the design rationale are shown in Table 2. A secretion signal has 
been placed to allow the protein secretion into the supernatant. This eliminates the need 
for laborious downstream processing after protein synthesis. GLuc’s native secretion 
peptide was used in all the test constructs. A Flag tag has been added to aid 
troubleshooting if the luminescence domain doesn't function. GLuc was used as a 
luminescence reporter. The positioning of Gluc part differs between the test variants. Trx 
tag was used as a solubility enhancer. The presence and absence of the tag changes 







Figure 2.6: 3D model showing different subparts of a synthetic protein. The Targeting 
domain (T-domain) coloured in magenta, is either a ScFv version or a diabody version. 
The bar depiction shows the arrangement order and the amino acid length of each 
domain. The arrow mark indicates the direction from the N terminus to the C terminus of 
the protein. (SS = Secretion signal, ST = Solubility tag) 
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Design elements Commonly used 
Notes on reviewed 
elements for the design 





GLuc SP, Kappa light 
chain SS 
Gluc SP* Eukaryotic   
G-luc signalling peptide is 






linkers, PAPAP   
(GGGGS)3 – Flexible -  
smaller size of the amino 
acids provides flexibility, 
hydrophilic, suitable for 
ScFv construction [24-28] 
 
(EAAAK)3 – Rigid – Forms 
alpha helix structures, keeps 
the distance between the two 
domains and to maintain 
their independent functions  
Can separate functional 
domains more effectively 
than the flexible linkers [24, 
29] 
(GGGGS)n was chosen 
where flexible linker 
was needed. This is rich 
in hydrophilic amino 
acids and allows the 
interaction between the 
domains due to its 
flexible nature [24]. 
Thus, increasing the 
stability and folding 
[24, 25, 30]. 
 
(EAAAK)n is chosen 
where the domains 
were supposed to stay 





Diabody only* - A 
combination of the 
above has been used to 
put the VH and VL of the 
same chains separate 
but allowing the two 
different ScFvs to 
interact forming the 
diabody complex. 
• Only with flexible 
linkers varying in 
number of (GGGGS)n 
• Only with rigid linkers 
with varying in 
number of (EAAAK)n 
• Alternating flexible 
and rigid linkers 
between the two 
variable chains and 
between the two ScFv 
fragments 
• Flexible linker 
between the VH and 
VL, with one rigid 3 
flexible and one rigid 
between the ScFv 
fragments 
• Without linkers 
• Linkers between each 





VH fragment, ScFv 
fragments, Diabody, 
Minibody, Antibody 
Smaller have faster blood 
and renal clearance 
 
ScFv and Diabody 
versions were modelled. 
The test variants differed 




Imaging element Gluc  
Gluc was chosen for its 
small size and that is 
secreted out of the 
cells 
All the design variants 
have Gluc domain. The 
arrangement of the domain 




Trx, NusA, SUMO 
[31, 32] 
• MBP- Huge size[33, 34], 
may change fusion 
protein structure,  
doesn’t require affinity 
tag, regarded as one of 
the best solubility 
tags[35, 36] 
 
• Trx – Small size, highly 
soluble, heat stable, 
requires affinity tag[31, 
37] 
One of the most used 
Tags 
 
• SUMO – small size, tight 
and rapid folding soluble 
structure[38], available 
for bacterial, yeast, 
insect and mammalian 
systems [39] 
Best for N-terminal 
fusion [38] 
contain His6 Tag  
SUMO* - Chosen for 
its small size  
Models with +/- SUMO 
placed both at N and C 





Poly-His Tag,  
Flag, c-Myc [40, 41] 
• Flag – Short, readily 
available commercial 
assays and is more 
hydrophilic than His [42] 
 
• His – Most common 
purification tag, short, 
commercially available 
assays, denaturing 
purification is possible 
[43]   
not preferred for 
antibody detection [43] 
Both Flag and Poly-
His are considered for 
computational 
modelling 
• Positioning of the tag 
was modelled both at 
N and C terminus of 
the POI, C terminus 
might show better 
results because signal 
peptide is at N- 
terminus[32] 
Table 1.2: Choice of subparts and design rationale for targeted synthetic proteins against ClfA 
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2.4.2 In silico-aided screening 
In silico screening involved rationally eliminating test variants with high chances of 
failing. For a synthetic protein with multiple subparts, each subpart serves for a defined 
function. The choice of the individual subpart depends on the overall function intended. 
In this case of designing proteins targeting S. aureus surface antigen ClfA, Table 1.2 
provides the decision rationale for selecting individual subparts. This is the first step in 
funnelling down the sample space of total possible test variants.  
Once the subparts are chosen, as mentioned in earlier, a synthetic protein with ‘n’ 
number of parts would have n! number of ways into which it could be assembled. All the 
logically possible assembly combinations have been modelled using I-Tasser. Multiple 
iterations of test construct variants have been generated while optimising linker types and 
sizes. During this process test variants were compared and noted for their structure quality, 
proper exposure of relevant tags and display of the paratope. Protein modeling and 
visualisation helped screening of several failed constructs. For example, in the model 
shown in Figure 2.7a the secretion tag is buried deep inside. This could potentially result 
in improper secretion. By increasing the linker sizes, the model on shown in Figure 2.7b 
shows an exposed secretion tag. Similar design corrections were made to ensure all the 
relevant domains are exposed appropriately. Solvent accessibility was used as an 
empirical measure for assessing proper exposure of a segment on the protein. For 






Figure 2.7: Informed screening using protein modelling and visualisation. (a) Showing 
the secretion tag in red, buried inside the structure. (b) Increasing the size of the linkers 
produced a conformation with appropriate exposures of relevant domains. (The above 




2.4.3 Test constructs for wet lab testing 
4 ScFv variants and 4 diabody variants were screened for wet lab synthesis and testing. 2 
test constructs were designed without the T-domain (binding site) which would act as 
internal negative controls for binding and as a positive control for luminescence. All the 







Figure 2.8: Test constructs for wet-lab testing. SD2 and SD6 lack the binding domain 
and were designed as internal negative control for binding. Constructs S1, S2, S3 and S4 
represent the ScFv version and the constructs SD1, SD3, SD4 and SD5 represent the 






2.4.4 Protein-Protein Docking 
Amino acid sequence and structural information of ClfA were obtained from the RCSB 






Figure 2.9: 3D structure of ClfA (PDB ID - 1N67). The minimal binding segment of S. 
aureus ClfA, containing two similarly folded domains is shown here.   
 
In silico docking was used to test the interaction of the test constructs with ClfA. The 
ClfA structure modelled by I-Tasser was used as the receptor. Active site on ClfA was 
highlighted and the boundaries for binding were defined. Upon docking, the highest free 
energy conformations were noted. Figure 2.10 shows the ScFv S3 bound to ClfA. The 
docking results and all the in silico data corresponding to the finalised 10 constructs are 





Figure 2.10: S3 ScFv (blue) docked with ClfA (red). Free energy change for the 
interaction was found to be (ΔG) -18.3. Protein docking was performed using AutoDock 

















of the active 
site (%) 




SD1 0.045 0.11 74.9 46.11 67.7 -13.6 99.03 38.42 
SD2 0.167 0.19 89 45.33 86.6 -11.7 37.53 30.92 
SD3 0.182 0.14 80.2 46.88 64.4 -15.2 85.83 35.97 
SD6 0.077 0.212 86.9 47.77 73.3 -11.2 24.33 18.42 
S1 0.057 0.24 78.1 45.88 60 -15.1 67.67 36.21 
S2 0.114 0.16 86.2 47.11 65.5 -15.4 54.47 31.08 
S3 0.071 0.162 82.8 46.66 64.4 -18.3 67.67 35.39 
S4 0.147 0.205 86.5 47.11 58.8 -16.9 54.47 31.08 
Table 1.3: In silico data obtained from various computational tools. From left to right, 
C-score (confidence score) from I-Tasser, TM score (template modeling score) as 
agreement between Rosetta and I-Tasser models, RC score (Ramachandran plot score), 
solvent accessibility of the active site (paratope regions), Free energy change from 




2.4.5 Wet-lab experimentation 
2.4.5.1 Protein production and secretion 
To validate the production of all the test constructs, luminescence being emitted from 
CHO cell supernatant was measured. 10 µl of each test construct was taken in a white 
corning 96 well plate. Supernatant media from a batch of non-transfected cells was used 
as a negative control. GLuc protein (NanoLight technologies) was used as a positive 
control. Figure 2.11 shows the luminescence from various constructs. The concentrations 
of the test constructs were calculated using the standard curve obtained from Gluc protein 
standards. As expected, both the control proteins SD2 and SD6 were the best produced. 























































Figure 2.11: Secretion of various test constructs. Relative luminescence units were 
corelated to concentration in mg/ml using a standard curve obtained from Gluc protein 
standards. SD2 and SD6 lack the T-domain and were used as internal controls. All the 




2.4.5.2 Binding to S. aureus ClfA 
In vitro binding was confirmed by measuring and comparing luminescence signals after 
binding. 108 S. aureus cells were treated with 1000 ng of each test construct. Experiments 
were performed on fresh subcultures of S. aureus to avoid the exopolysaccharide 
formation. Bound luminescence from each test construct is plotted in Figure 2.12. S. 
aureus cells only (without synthetic protein) were considered to measure the background 
luminescence. The construct SD2 and SD6 had the lowest bound luminescence signal. 
Both the constructs lack the binding domain and hence cannot bind to ClfA. ScFv S1 
showed the highest luminescence signal. The data were plotted again in different graph 
format to determine the difference between ScFvs vs Diabodies, but no significant 
correlation was observed. The data set size was also too small for such comparisons. With 





Figure 2.12: Bound luminescence. Luminescence after binding to ClfA on S. aureus. 108 
S. aureus cells were incubated with 1µg of each test construct for 1 h. Cells without 
treatment were used as a background. SD2 and SD6 were used as negative controls for 
























































































































2.4.5.3 Dose response experiments 
Dose response experiments were performed using two Gram-positive and two Gram-
negative strains. Three different concentrations of the synthetic proteins and three 
different bacterial concentrations were used during optimisation. 
2.4.5.3.1 Synthetic protein dose response 
3 different concentrations of the test constructs were tested for their binding to ClfA. 0, 
0.50µg and 1µg of test construct were incubated with 108 cells of S. aureus 959. Bacterial 
cells were washed 3 times and resuspended in PBS. All the samples in triplicates were 
placed in a corning 96 well white plate. Luminescence was measured after adding 50µl of 
coelenterazine. E. coli DH5alpha, Salmonella enterica Typhimurium 7207 and 
Streptococcus agalactae (GBS) strains were used as negative controls to measure 
selectivity towards S. aureus. Optimisation was carried out on all test constructs using the 
above mentioned 4 bacterial strains. ScFv S1 construct was again the best performer. The 
results of the synthetic protein dose response of S1 were shown in Figure 2.13. The 
selectivity of binding in Figure 2.13b is the ratio between luminescence from S1 bound to 
S. aureus and Streptococcus agalactae. The data in Figure 2.13 clearly shows the 






Figure 2.13: Synthetic proteins dose response of S1 with 108 bacteria: a. shows the 
relative luminescence units from four different bacterial strains treated with 3 different 





2.4.5.3.2 Bacterial cell dose response 
Three different concentrations of four bacterial strains (two gram-positive and two gram-
negative) were treated with 1000ng of each test construct. Bacterial cell dose response 
was carried out on S. aureus 959. E. coli DH5alpha, S. Typhimurium and S. agalactae 
(GBS) strains. Bacterial cells were washed 3 times and resuspended in PBS. All the 
samples in triplicates were placed in a corning 96 well white plate. Luminescence was 
measured after adding 50µl of coelenterazine. ScFv S1 showed the highest luminescence 






Figure 2.14: Bacterial cell dose response of S1 (a). Relative luminescence units from 
four different bacterial strains with 3 different concentrations of bacterial cells. (b) 
Difference in signal intensity of the luminescence emitted by S1bound to S. aureus when 




2.4.5.4 Blocking with human fibrinogen 
To confirm the binding of S1 specifically to ClfA, the S. aureus cells were incubated with 
different volumes of human fibrinogen to block ClfA. 108 S. aureus cells were incubated 
with 0, 10 and 250 µg of human fibrinogen for one hour at room temperature. The cells 
were washed 3 times with PBS and then incubated with 10 µl of S1 supernatant, 1 h at 
room temperature. Bacterial cells were washed 3 times and resuspended in PBS. All the 
samples in triplicates were placed in a corning 96 well white plate. Luminescence was 
measured after adding 50 µl of coelenterazine. No binding was expected upon addition of 
S1. The luminescence readings were plotted in Figure 2.15. As expected, the increase in 
fibrinogen concentrations led to decrease in luminescence. Fibrinogen successfully 





Figure 2.15: Blocking with human fibrinogen. (a) Shows decreasing luminescence 
intensity with increase in fibrinogen concentration. (b) showing percentage decrease in 




















































































































2.4.5.5 Optimal performer (Selectivity + Intensity +Normalised performance) 
After the wet-lab validation of all the 10 test variants, it was intended to carry out an in 
vivo imaging study using the best performing test construct. The choice of the best 
construct depends on overall performance. Overall performance can be defined as the 
degree to which the designed protein would perform ultimately on the user defined 











Although all the test constructs performed the user defined function, they differed in their 
performance quality. Arbitrary numbers were given to the coefficients reflecting the 
relative importance of each parameter. However, in this case S1 was outperforming all 
the other test constructs. After choosing S1 as the best performer, keeping in mind the 
demands of in vivo imaging, efforts have been made to improve the signal intensity of S1.  
2.4.5.6 Nanoluc as the luminescence part 
Previous literature has reported that an engineered luciferase obtained from a deep-sea 
shrimp (Oplophorus gracilirostris) (Nanoluc) has better brightness than Gluc in vivo [44]. 
In an effort to improve the brightness of S1, the Gluc domain was swapped with Nanoluc, 
and a new Nanoluc version of S1 (NS1) was synthesised. Synthetic protein dose response 
and bacterial cell dose response for NS1 were examined using S. aureus as the target and 
E. coli as a negative control. 20 µl of protein supernatant was added to each sample and 
incubated for 1 h at room temperature. Luminescence was measured after adding 50 µl of 
coelenterazine. After 3 subsequent PBS washes, the samples were taken into a 96 well 
corning white plate. The data for the dose response experiments are plotted in Figure 2.17. 
However, the brightness (RLU) in in vitro experiments of NS1 was found to be 





Figure 2.17: Synthetic protein dose response and bacterial cell dose response of NS1 
(a) Synthetic protein dose response was carried out on 108 bacterial cells of S. aureus 
and E. coli. The bacterial cells were treated with varied volumes of the protein 
supernatants. (b) Bacterial cell dose response was carried out using 0, 106, 107 and 108 
cells. The luminescence signal from the S. aureus samples were significantly higher than 
that of E. coli samples, indicating binding to S. aureus. The dose response experiments 

















































































































In this chapter, a workflow was generated for the 'design, build and test' of synthetic 
proteins. Various computational tools were used to ensure proper functioning of the 
subparts. Such an approach validates the structure before wet lab synthesis and testing. 
Such a computationally informed design strategy would empower wet lab biologist with 
prediction capabilities. In my cases during the process, modeling helped to realise pitfalls 
in the design. One such example was shown in Figure 2.7, where the secretion tag was 
hidden inside. Similar non-functional designs were also spotted with the Flag tag. Both 
the secretion tag and the Flag tag are located at the extremes of the polypeptide chain. It 
is crucial for the tags to remain exposed for their full functionality. Without protein 
modeling, such failed experiments end up in the wet lab validation and cause time and 
capital wastes.  
In this work, over 200 different test variants were designed and modelled. Over 
50 test variants were subjected complete computational analysis. This process is 
analogous to high throughput screening that is observed in wet lab drug design. However, 
the in silico screening only takes a fraction of the time to test the constructs in the wet lab. 
This work heavily relied on computational tools. However, it must be noted that the 
accuracy of each computational tool is subjective to each protein. Predictions of synthetic 
proteins that resemble close similarity to naturally existing proteins have higher 
confidence levels and accuracy. Community-wide, worldwide studies such as CASP 
(Critical Assessment of protein Structure Prediction), CAPRI (Critical Assessment of 
PRediction of Interactions) and CAFA (Critical Assessment of Functional Annotation), 
organise regular blinded challenges to compare the performance of various computational 
tools for proteins [45-47]. With artificial intelligence, neural networks, deep learning and 
increased computational power, the road ahead is promising. The strategy presented here 
will grow in accuracy as the individual tools get updated.  
The aim of this chapter was to develop a targeted report protein specific for S. 
aureus. ClfA was chosen as a test model for the in silico aided synthetic protein design 
strategy. Abundance of literature on the structure of ClfA, ready availability of the amino 
acid sequences of ClfA and its targeting monoclonal antibody tefibazumab (also known 
as mAb 12-9 and Aurexis) encouraged the pursuit in this direction. Although, mAb 12-9 
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recognizes ClfA on S. aureus cells with a high affinity the antibody has failed in the 
clinical trials (no significant advantage over a placebo was observed in relapse of 
bacteremia) [48]. S. aureus employs various virulence and immune evasion factors to 
survive in the host. This could be one of the prime reasons for the failure of the antibodies 
targeting a surface antigen like ClfA. Thus, targeting multiple virulence factors could be 
a strategy to explore [49]. 
In vitro testing was carried out to validate secretion and functioning (binding and 
luminescence) of the synthetic proteins. Throughout the work, luminescence was used to 
inform the protein production, binding and selectivity. The S1 test construct clearly stood 
as the best performer amongst all other test construct variants. With the encouraging 
results observed in the dose response assays, S1 was identified as a candidate worthy of 
examining in a future in vivo setting. Although Gluc is a widely used as an imaging 
module in preclinical research, the issues with signal intensities and tissue absorption still 
remain. Hence the Gluc was replaced with Nanoluc, to increase the signal intensity. The 
Nanoluc system has been shown in previous literature, to have a significantly higher 
brightness and prolonged half-life, when compared to Gluc[50]. In silico modelling and 
computational validation was repeated on NS1 construct, prior to synthesis. In this study, 
the luminescence signal from NS1 was observed to be lower than its Gluc counterpart. 
Identifying the reason for this behaviour was beyond the scope of this project. However, 
as previously studied in literature, the luminescence emitted from Nanoluc lasted 
significantly longer than luminescence from Gluc. This might be a key feature that would 
score Nanoluc as a better alternative to Gluc in in vivo applications.  
The in vitro studies in this work, provided a preliminary understanding of the basic 
functioning of the protein and validated the in silico design strategy. The luminescence 
and binding assays validated the functioning of each subpart on the test construct and its 
functioning as intended. With the aim of validating protein sizes, integrity and 
concentration, Western blots using anti-Flag antibodies were performed, but to no avail, 
despite multiple attempts (data not shown). Similar anti-Flag Western blots were readily 
achieved in Chapter 5 work. The failure to detect these synthetic proteins by Western blot 
could be due to some reasons unique to these synthetic proteins.  Further wet-lab assays 
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such as FACS using anti-Flag fluorescent antibody would also be beneficial to reconfirm 
the binding of the synthetic protein to ClfA. 
In silico myriad problem Table 3 shows a summary of numerical evaluation 
performed using various computational tools. Each individual tool informs the quality of 
a design parameter. For example, the RC plot provides an RC score, modeling provides 
the C score etc. These design parameters relate to the functioning of each individual 
subpart. While screening for the best performer, a holistic overall performance should be 
considered rather than functioning of individual subparts. In mathematics, this is a 
common problem observed in cases such as buying a house or buying a car. A decision 
must be taken on the holistic level rather than a subpart level. There is no tool available 
to predict the overall performance of test construct. Such a tool would be pivotal in in 




Over 50 different multi-part test constructs targeted to S. aureus surface antigen ClfA 
were modelled and validated using various computational tools to inform and guide 
downstream wet-lab experiments. Following in silico design and analyses, 10 test 
constructs against ClfA were produced in CHO cells and tested for specific target binding 
in vitro. This study demonstrated the proof-of-concept of the design-model-build-test 
strategy of targeted synthetic proteins, using S. aureus surface antigen ClfA as a model 
target. Finally, a target-specific synthetic protein platform for bacterial imaging has been 
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Background  Protein engineering and synthetic biology stand to benefit immensely from 
recent advances in in silico tools for structural and functional analyses of proteins. In the 
context of designing novel proteins, current in silico tools inform the user on individual 
parameters of a query protein, with output scores/metrics unique to each parameter. In 
reality, proteins feature multiple ‘parts’/functions, and modification of a protein aimed at 
altering a given part, typically has collateral impact on other protein parts. A system for 
prediction of the combined effect of design parameters on the overall performance of the 
final protein does not exist. 
Aims  Function2Form Bridge (F2F-Bridge) aims to address this gap by 
combining the scores of different design parameters pertaining to the protein being 
analysed into a single easily interpreted output describing overall performance. The 
strategy comprises 1. A mathematical strategy combining data from a myriad of in silico 
tools into an OP-score (a singular score informing on a user-defined overall performance); 
2. The F2F-Plot, a graphical means of informing the wet-lab biologist holistically on 
designed construct suitability in the context of multiple parameters, highlighting scope for 
improvement.  
Methods & Results F2F predictive output was compared with wet-lab data from a 
range of synthetic proteins designed, built and tested for this study. Statistical/machine 
learning approaches for predicting overall performance, for use alongside the F2F plot, 
were also examined. Comparisons between wet-lab performance and F2F predictions 
demonstrated close and reliable correlations. 
Conclusion  This user-friendly strategy represents a pivotal enabler in increasing 





3.2.1 The world of in silico aided protein design 
Proteins are multi-functional biomolecules that perform, mediate and regulate various 
fundamental functions of life. Over the last 50 years our understanding of proteins and 
our ability to engineer them has improved exponentially. While proteins find their 
applications in various fields, biochemical and medical applications have taken the 
driving seat commercially. Since 1982, when insulin, the first recombinant protein was 
produced the biotechnological way, the market value for protein-based therapeutics has 
seen a significant increase, with the market value of bioengineered protein drugs is 
expected to reach $336.9 billion by 2025 [1]. Nature has sampled only a small fraction of 
the theoretical combinations of amino acids that are accessible to proteins [2] due to the 
constraints put in place by evolution. Synthetic protein design represents a vast sea of 
possible space available to be explored. While multiple industries have the potential to 
exploit non-natural proteins as components of their products or processes, this potential 
cannot be fully realised without reliable control over protein design. 
 Understanding the interplay between structure and function of proteins is 
pivotal in protein design. Techniques such as NMR spectroscopy and X-Ray 
Crystallography have revealed the structures of over 100,000 proteins and have aided the 
establishment of protein databases [3], which in turn have facilitated in silico protein 
structure and function prediction based on the amino acid sequence. The need for a faster 
and affordable way to predict the putative structure of a protein paved the way for 
computational protein modelling [4]. In silico-aided protein design uses computational 
strategy for designing and building proteins that perform a specific function(s), in a user 
defined setting. Computational methods for structure modelling, docking and function 
prediction provided in silico alternatives for screening protein sequences, creating 
variants of a specific design [5] and building new de novo structures [6] . As a 
consequence of increasing computational power, the power of in silico protein structure 







3.2.2 The overall performance problem:  
Multiple related parameters and the myriad of in silico tools  
Computational tools are now available to predict protein structure, active sites, chemical 
properties and interactions with other proteins [7-11]. In some cases, these tools could 
also be used to redesign existing proteins [12] or even design entirely new proteins, in the 
rapidly evolving field of de novo design [13-16]. Unfortunately, a side effect of these 
rapid advances is that, it is becoming difficult to bridge the gap between these advances 
in computational technology and their originally intended wet-lab applications by 
biologists. ‘Outsourcing’ the required in silico activity by end users (wetlab biologists) 
entirely to ‘dry-lab’ specialists dramatically reduces the potential of in silico modelling, 
‘User empowerment’ is key to translating this potential. 
Designing a protein involves defining an overall function (Box 1) and associating 
it with a 3D structure which is coded into an amino acid sequence [17]. In most cases, the 
overall function of a protein is a combination of several individual sub-functions. To 
achieve the overall function, fusing different sub-function parts (Box1) has been the most 
popular strategy to date. In recent years, de novo protein design has been used to obtain 
amino acid sequences which fold into a required 3D structure for a defined function. In 
both of these cases, several test sequences are generated to validate their performance 
against the defined overall function. In silico protein design aims to find a ‘best-fit’ test 







The overall performance of a test sequence is a collective functioning of all the individual 
sub-function parts in concordance. In most cases, the quality of the functioning of the 
individual sub-function parts is interdependent. Wet-lab validation of each test sequence 
is time consuming, labour intensive and expensive. Moreover, improving a given 
sequence by modifying individual subfunction part sequences without a holistic analysis 
on the overall performance represents an ad hoc approach prone to low success rates.  
 
Box 1: Definitions and commonly used terms 
  
Overall performance: The degree to which the designed protein would perform the 
defined Overall Function 
  
Sub-function part: A part of a protein that is responsible for a particular sub-function. A 
Sub-function part may represent a sequence for a specific known protein or a part of a 
protein which has a defined distinct function. 
  
Design Parameters: Parameters such as hydrophobicity, solubility, structure, active site 
exposure etc., influence the overall performance of a protein. While these parameters are 
tools for studying the nature of existing proteins, the same parameters, in protein design, 
can be used as controllers to dictate the overall performance of a protein. Such parameters 
that dictate the overall performance of a designed protein are grouped under an umbrella 
term called ‘design parameters’. 
  
The overall performance prediction problem: The complex relationship between the 





Figure 3.1. The in silico aided protein design process and the overall performance 
problem. Multiple test sequences are generated for a user-defined overall function (The 
overall function is the collective functioning of all the sub-function parts). Sub-function parts 
and the test sequence build dictate the 3D structure. Test sequences are subjected to in silico 
modelling and multiple analyses. F2F bridge provides an objective, single metric and a 




Computational tools are now available to predict protein structure, active sites, chemical 
properties and interactions with other proteins. These tools score and inform the quality 
of the individual design parameter using their respective conventional metrics. While 
these metrics define the quality of the individual parameter in the design, the combined 
effect of the design parameters (Box 1) on the overall performance is a question yet to be 
answered. This has been referred as the ‘overall performance problem’ (Box 1). The 
overall performance problem is a huge challenge in biology wet-lab experimentation but 
not completely new in a mathematical perspective.  
Recent advances in machine learning and data analyses have solved similar 
situations. For example, ‘selecting a suitable house in a new city’ or ‘selecting an 
electronic device that fits my purposes’ and ‘selecting a car appropriate to my needs and 
budget’. All these situations are mathematically similar to an extent. The parameters affect 
the overall performance and the best fit is chosen based on scoring and ranking the 
potential fits, based on the user’s needs. Although the overall performance problem has 
been addressed in other contexts, in the scientific field of protein design, formulating a 
mathematical model poses a greater challenge. This is due to (i) the lack of a reporting 
system for negative results, (ii) time constraints in biological experimentation and (iii) the 
lack of standardization of measurement units in many areas of biological research. 
3.2.3 Machine learning methods for proteins 
Our understanding of protein function and the structure-function relationship has been 
enriched by computational algorithms and in silico tools. Machine learning algorithms 
and strategies have been used for over a decade now to solve sequence-structure-function 
relationships of proteins [18]. Latest advancements in machine learning approaches and 
current strategies used to predict the function(s) of a protein are reviewed by Bernardes et 
al [19].  
In the lights of de novo protein design it is now possible to design proteins with 
user defined functions and shapes. In such cases, while predicting the overall function of 
a protein is useful, the extent to which these designed proteins perform their function is a 
crucial element. Design improvements could be made and measuring the overall 





3.2.4 A novel mathematical strategy using machine learning approaches. 
In this work, F2F-Bridge is introduced as a novel mathematical strategy aimed at 
predicting the overall performance of a synthetic protein. Several test sequences were 
designed for a defined overall function. The individual scores for all the different design 
parameters pertaining to each test sequence are condensed into a graphical output. The 
result is a visual and numerical evaluation of the test sequence. The graphical output (F2F-
Plot) and the numerical evaluation (OP-score) together form a novel mathematical 
strategy (F2F-bridge) that scores, ranks and predicts the overall performance of the given 
set of test sequences. This method combines user input with in silico data, to give insights 
into the predicted overall performance of a test sequence. With the view to eventually 
developing a robust tool for protein performance prediction, the relationship between in 
silico and laboratory data for test proteins was also examined using two different strategies 
for feature selection and predictive model building. LASSO and regression-based 





3.3 MATERIALS AND METHODS 
3.3.1 In silico design of test sequences: 
The test synthetic proteins examined were the ClfA- (Chapter 2) and MUC1- (Chapter 4) 
targeted Gluc synthetic proteins. Each construct was designed to have a luminescent 
domain, a binding domain, a solubility tag and a secretion signal. All parts are linked in 
all possible permutations using different rigid and flexible linker sequences [20] (see 
schematic in Chapter 2 Figure 2.6). Variable heavy and light chain AA sequences from 
different antibodies were used as the binding domains, from an antibody targeting either 
cell surface associated epithelial mucin 1 (MUC1; mammalian antigen) and Clumping 
factor A (ClfA) of Staphylococcus aureus (bacterial antigen). Test sequences were 





3.3.2 Data Generation: 
The different in silico features analysed in relation to the overall performance of the test 
protein, and how they are generated is outlined in Table 3.1. 3D structure prediction, size, 
instability index and size were obtained by providing the amino acid sequence of the 
protein as an input to the server. Docking, model quality, active site solvent accessibility, 
surface hydrophobicity, potential active sites required a .PDB file as an input. In almost 
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3.3.3 Wet-lab validation 
Two biological facets were used to assess the effectiveness of the functional prediction 
strategies – i) binding; ii) secretion. 
Sub-function parts on the test sequences include: (i) Active site: Heavy and light chains 
of anti-MUC1 antibody (C595) and anti-ClfA antibody were fused with EAAAK (rigid) 
and GGGGS (flexible) linkers to obtain Monospecific bivalent diabodies and Monovalent 
ScFVs (monobodies), (ii) Secretion signal: Gaussia luciferase’s native secretion signal, 
(iii) Solubility enhancer: SUMO tag, (iv) Reporter: Truncated version of GLuc was 
used as a luminescence reporter. (v) Detection tag: Flag peptide was used as a detection 
tag for downstream assays. See Fig 4. 
 Presence or absence of certain sub-function parts or their design orientation 
has a significant effect on the overall performance of the protein and should be accounted 
carefully in the design phase. In this case, over 50 different amino acid sequences were 
designed against each target. Of these, 8 variants per target were synthesised for testing 
in the wetlab. These test sequences vary in (a) (+/-) solubility enhancer, (b) (+/-) and 
positioning of Active site and (c) the type/format of Active site. All these test sequences 
were tested for their overall performance. Wet lab data were used to validate and improve 
the results from the F2F-Bridge. An outline of the laboratory workflow can be seen in 
Figure 3.2, and a more detailed description on synthesis and build of test sequences can 
be found in the Supplementary materials.   
  
3.3.4 Data generation from wet lab experiments 
Binding assays: As outlined in Chapter 2 and Chapter 4. Briefly, 108 Staphylococcus 
aureus TCH959 (naturally bearing clfA) or 106 MCF7 cells (naturally bearing MUC1) 
were blocked with 5% BSA for 2 h followed by incubation with supernatant containing 
each test construct. Cells were washed 3 times and resuspended in PBS. Luminescence 
was measured using Promega GloMax® 96 luminometer. In this case, since bound 
luminescence is the overall function, the luminescence readings corresponding to each 





Figure 3.2: Workflow of wet lab validation of the test sequences. Selected test variants 
were assembled into a plasmid. CHO cells were transfected with the plasmid containing 
the test variants. Cell supernatant containing the synthetic protein was collected and used 





3.3.5 Function2Form Bridge: 
Function2Form algorithms were written in R programming language with the help of 
Tangney Lab bioinformatician Sidney Walker. Individual scores from all the respective 
in silico tools mentioned in Table 3.1, are tabulated and the resulting file is given as an 
input for F2F algorithm. The first row in the table consists of user required input values, 
which act as a benchmark to which the parameters of the test sequences in future would 
be compared. Some of these benchmark values such as C-score RC score etc are exactly 
the same as given by the tool developer Whereas, for parameters such as surface 
hydrophobicity, size or number of required active sites, the user can input values 
according to the design requirements. The F2F bridge in this study, uses the scores from 
7 different in silico parameters but the scope of the tool is not limited only to these. 
Number and the type of in silico parameters used differ based on the defined overall 
function.  
For a particular defined overall function, the choice of in silico parameters is based 
on prior knowledge and literature research manually. Such a manual selection counts all 
the parameters as equally contributing players. In reality however, the contribution or the 
effect of a parameter on the overall performance differs case by case. This is understood 
by considering house picking problem as an analogy. While choosing or buying a house, 
the locality, distance to work, cost, number of bedrooms etc are all influencing parameters. 
However, the importance of each parameter differs for every individual. Hence 
prioritising or weighing the importance of each parameter is necessary.  
In this work, machine learning methods such as random forest and lasso regression 
have been used for feature selection. These methods help weigh the in silico parameters 
by considering their importance towards the overall performance. Wet lab luminescence 
data was used to train the models. The result of the F2F bridge is a radar plot (F2F plot) 
and an overall performance score (OP score). The F2F plot is a graphical representation 
of the benchmark (user defined) values and the scores of the in silico parameters 
corresponding to the test sequences. The area between the two curves indicate the 
disagreement between the user requirements and the design. In an engineer’s eye, this is 
a region for improvement. The overall performance score (OP score) is a grand average 
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of the absolute distance between the user defined curve and test sequence curve generated 
by the F2F bridge. See Figure 3.3. 
        
3.3.6 Generating the OP score: 
(i)             The values are converted into a single scale 
 
𝒊 = (((𝑶 −  𝑶_𝒎𝒊𝒏))/((𝑶_𝒎𝒂𝒙 −  𝑶_𝒎𝒊𝒏))) ∗  (𝑵_(𝒎𝒂𝒙 ) −  𝑵_𝒎𝒊𝒏 ) + 𝑵_𝒎𝒊𝒏 
 
Where O is the old range and N is the new range, which in the case of the F2F function is 
always 0-100. 
 
(ii)           F2F function then iteratively scores each test sequence 
 
𝑂𝑃 𝑆𝑐𝑜𝑟𝑒 𝑜𝑓 𝑥 =   (𝛴|𝑥𝑖 − 𝑦𝑖|)/𝑛 
 
Where x is the test sequence, y is the benchmark values, i refers to the ith observation 










Figure 3.3: F2F plot is a graphical representation of the merits and pitfalls of the design. 
The overall performance score is the grand average between the red and blue curves 
shown in the plot. In a high throughput setting, this could be used to rank the test 





3.3.7 Statistical and machine learning methods: 
As discussed above, machine learning methods were used to design a system of weights 
for F2F bridge. The methods used and their working are detailed in Table 3.2. 
 
Statistical analysis: All statistical testing was performed in the base R environment 
v3.4.3 [25]. The LASSO regression feature selection method was implemented using the 
Glmnet library v2.0-16 [26], and the Random Forest regression tree analysis was 
performed using the RandomForest library v4.6-14 [27]. The radar plot within the F2F-
bridge function was implemented with the fmsb library, v0.6.3 [28]. Visualisation was 







Lasso regression After regularization, the parameters with  
non-zero coefficients are selected to be 
part of the final model [30] 
Random forest A variable importance plot is generated 
using the in silico parameters as input, 
and wet-lab luminescence as an indicator 
of overall performance.[31] 






3.4.1 Predicting the ‘Overall Biological Performance’ - Unsupervised and 
unweighted F2F. 
F2F-plot was used to score 16 different test sequences. Figure 3.4 and 3.5 show the F2F-
plots and respective OP scores for the test sequences against ClfA and MUC1 
respectively. The OP score is inversely proportional to the rank of the test sequence. 
Lower OP score indicates better predicted overall performance and a high score indicates 
a poor performance. For example, in Figure 3.4, antiClfA Monobody 2 (pink shaded 
region) has the lowest OP score and hence predicted to be the best performer. In this case, 
although the instability index of the test sequence is in disagreement with the desired 
output, on a holistic level, antiClfA monobody 2 has the lowest disagreement and hence 
predicted to be the best performer. On the other hand, antiClfA diabody 2 was predicted 
to be the worst performer based on its high disagreement on instability index, docking 
affinity and solvent accessibility.   
 
(Note: at this level, the method is still blind folded). 
 
To assess the accuracy of F2F prediction the F2F-prediction of overall biological 














Table 3.3: F2F plot vs Wet lab. Test sequences in both the tables were ranked by their 
F2F score, and coloured from green (best performing protein), through yellow to red 







The results from Table 3.3 indicate a general guide on how F2F bridge predicts the 
performance and could be used to rank the test sequences based on their performance. 
However, there was no statistically significant correlation observed between the two 
panels because of the limited size of the database. Similar analysis was repeated with 
‘luminescence’ as overall performance. There was no significant relationship was 
observed.  
 
3.4.2 Applying machine learning methods to F2F bridge 
2.4.2.1 Improving F2F bridge with supervised and weighted machine learning. 
As discussed above the blind method accounts every in silico parameter as an equal 
contributor to the overall performance. In common terms, weighing the influence/effect 
of each parameter on the overall performance is crucial for an accurate prediction. 
Machine learning methods, Lasso regression and random forest regression tree analysis 
were deployed to address this problem with the blind method. ‘Selection of variables’ and 
‘regularisation’ were introduced to distinguish ‘big players’ or ‘major contributors’ from 
the panel of in silico parameters.  
Two wet lab outcomes are used as defined overall functions. All the analyses were 
carried on both ‘bound luminescence’ and ‘secreted luminescence’ readouts of the 
designed test sequences.  
 
3.4.2.2 Regression analysis, selection of variables and regularisation 
Applying machine learning methods for biological data is not entirely new and is a rapidly 
growing field. In the last 10 years, machine learning algorithms have been extensively 
used for protein structure and function prediction. Introduction of artificial intelligence 
based strategies have strengthened the field. Recently Google’s AI firm ‘DeepMind’ 
introduced an algorithm called ‘AlphaFold’ and this has shown a significant improvement 
in structure prediction accuracy and gained wide attention. Although the recent advances 
show promising prospects, in most cases, however, the underlying mechanisms of 
function prediction and the relationships between the structure, function and the in silico 
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parameters of a protein, are not fully understood. Lack of large biological data to aid the 
machine learning and the huge number of variables in biological experimentation are a 
few bottle necks. 
To improve the prediction accuracy of F2F bridge, distinguishing the ‘big players’ and 
accounting for the contribution of each parameter towards the overall performance is 
crucial. In mathematical terms (machine learning terminology) this is called feature 
selection. Linear regression models and decision tree based models are two widely used 
methods of analyses for feature selection. 
In this work, lasso regression (linear regression) and Random forest (decision tree) based 
methods were used for feature selection and to explore the possibility of providing weights 
to the in silico parameters based on their contribution towards the overall performance. 
 
Note: Regression analysis considers all the in silico parameters as independent variables. 
Which is not the ideal.  
 
3.4.3 LASSO (Least absolute shrinkage and selection operator) regression 
Lasso reduces the less important feature’s coefficient to ‘0’ and thereby, eliminating some 
features entirely. This will pick the most important features and hence is called feature 
selection. This is a very commonly used method in cases where there are high number of 
features. Figure 3.6 shows the LASSO regression analysis of bound luminescence for the 
designed test sequences. The features/parameters that deemed to have the maximum effect 
on each overall function is shown below. For the test sequences against MUC1, the 
parameters such as Docking Affinity, Iso-electric point, Hydrophobicity and Solvent 
accessibility deemed to have the maximum influence on the overall performance. In the 
case of test sequences against ClfA, Hydrophobicity and Instability have shown the 
maximum influence. However, no linear relationship was detected when the predicted 
parameters were input into a linear model. 
123 
 
Figure 3.6: Output from LASSO regression analysis for bound luminescence. Each line 
in the graph corresponds to an in silico parameter used in the F2F-Bridge. (A) shows 
results for antiMUC1, and (B) shows results for antiClfA. This shows that Lasso 
regression analysis was capable of identifying relationships between the in silico 





Test sequences P-Value Adjusted R Squared 
antiClfA 0.507 -0.06 
antiMUC1 0.867 -0.6 
Table 3.4: Results of multiple regression analysis of features selected by Lasso 





The lasso regression has successfully (i) detected the potential relationships between the 
wetlab output (bound protein luminescence) and the predictive features (in silico 
parameters) and (ii) the major contributors, i.e. ‘big players’ have been identified. 
However, no predictive model could be constructed. This could be due to (a) the small 
size of this dataset and (b) too many variables present from a wet lab perspective. 
Variables in wet-lab experimentation are one of the major bottlenecks for the application 
of machine learning techniques. With automation technology providing aid and reducing 
human intervention this could be brought down.  
 
3.4.4 Secreted luminescence as overall performance. 
In the above scenario, ‘bound protein luminescence’ has been used as a test variable. The 
two groups of proteins (anti-MUC1 and anti-ClfA), in this case, were considered 
separately due to their binding towards different targets. However, ‘luminescence’ only 
from the secreted proteins could also be used as a test variable. In this case, the two groups 
(antiClfA and antiMUC1) could be combined into one single dataset and can be directly 
compared. This doubled the sample size. This has given the freedom to use one set of 
proteins (anti-ClfA) as a training set and the trained model was used to predict the 
performance of the other set (anti-MUC1).  
 In Figure 3.7, Lasso regression function was used to investigate the 
relationship between the in silico parameters and the wetlab output (luminescence due to 
secretion of anti-ClfA test sequences). The ‘big-players’ (in silico parameters which play 
a major role in dictating the performance) for luminescence due to secretion were 
identified by Lasso regression. A linear model was then generated, using the ‘big players’ 
identified by Lasso, to examine the degree to which they explained the test variable 
(luminescence due to secretion).  The linear model generated this way explained 84.6% 
of the variability in the test variable (luminescence due to secretion), with a p-value of 
0.004. This gave us the confidence to explore the utility of a lasso dictated linear model 
as a potential overall performance predictive tool. The experimentally determined 
performance (luminescence levels) were correlated with the Lasso model predicted 
performance.The results of correlation and the correlation coefficients of the individual 
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test sequences against their luminescence are plotted in Figure 3.7 and in Table 3.5.  Both 
anti-ClfA and anti-MUC1 sets showed significant correlations, with Rho values 0.93 and 
0.71 respectively. 
 
Note: ‘Big players’ i.e. in silico parameters that have major contribution towards the 
overall performance, are subjective to the user defined overall function. The ‘big players’ 






Figure 3.7: (A) Results from lasso feature selection (antiClfA test sequences). In this 
instance, Isoelectric and Instability index appear as big players and are predicted to have 
the most effect on the test variable. Multiple linear regression was used to test the 
relationship between the experimental luminescence (wetlab) and features selected by 
Lasso regression. The model was found to be significant and explained 84.61% of the 
variability in the test variable and has a p-value of 0.004. (B) Correlation plot of 
experimental values of test variable vs Lasso directed linear model predicted values of 
test variable. AntiClfA test sequences (in blue) are used as the training set and AntiMUC1 





   All Anti MUC1 Anti ClfA 
Rho 0.846 0.71 0.93 
P value 0.0009 0.04 0.0006 
Table 3.5: Rho (correlation coefficient) and P values of the Lasso directed linear model.  






3.4.5 Random Forest regression tree analysis as an alternative performance 
prediction method. 
To increase the versatility of F2F Bridge, random forest regression tree analysis has been 
used for a non-linear model. Similar methodology to Lasso regression was implemented 
within random forest. Anti-ClfA test sequences were used as the training set and the anti-
MUC1 test sequences were used as the test set. The results from the random forest 
regression model are shown in Figure 3.8. The model was successfully able to explain 41 
% of the variability in the test variable (luminescence from secretion). Table 3.6 shows 
the correlation values between the random forest algorithm predicted luminescence and 
experimental luminescence. Significant correlation was observed between the test 
variable (secreted luminescence) predicted by the random forest and the experimentally 
determined values. When the same was repeated using the bound luminescence as test 
variable, no significant results were observed. With bigger datasets for training, this 
accuracy can only increase. Table 3.7 shows a summary of all the analyses and their 






Figure 3.8: Random Forest regression tree analysis summary.  (i) Mean node purity for 
each predictive feature. Smaller values indicate the high importance of the feature to the 
model. (ii) The trained model explained 41% of the variability in experimentally 
determined test variable (secreted luminescence). The model predicted luminescence 
values were correlated with experimentally determined luminescence values. The model 






   antiClfA antiMuc1 Total 
P value 0.002 0.05 1e-5 
Rho 0.92 0.71 0.87 
















The F2F plot was able to 
provide a guide for the 
expected performance of the 
test sequence when the test 
sequences were ranked by 
OP score and by wet lab 
output, and the 
accompanying plot was able 
to inform on how to improve 
the test sequence. No 
statistically significant 
relationship between OP 
score and wet lab output 




selection and linear 
model building 
Binding antiClfA and 
antiMUC1 
LASSO regression analysis 
was able to detect discrete 
patterns in the data, showing 
Hydrophobicity and 
Isoelectric point both to have 
a positive relationship with 
bound luminescence in 
antiClfA. In the case of 
antiMUC1 Docking Affinity 
and Solvent accessibility 
were shown to have a 
positive effect, Isoelectric 




dictated linear model 
as a predictive tool 
Binding antiClfA and 
antiMUC1 
The models predicted in the 
above analysis were unable 
to exaplain any of the 
variability in the bound 
luminescence of antiMUC1 




selection and linear 
model building 
Luminescence antiClfA LASSO regression analysis 
was able to detect discrete 
patterns in the data, a linear 
regression with solvent 
accessibility and instability 
was able to explain 86.4% of 
the variability in 




dictated linear model 
as a predictive tool 
Luminescence antiClfA and 
antiMUC1 
The model created in the 
above test was used to predict 
luminescence values for both 
antiClfA and antiMUC1. In 
both cases these predictions 
showed strong positive 
correlations with the 
experimental luminescence 
values which were 
statistically significant. 
Random Forest 
regression tree model 
building 
Luminescence antiClfA A regression tree 
implemented with 
randomForest was able to 
explain ~41% of the 
variability in the 





Forest regression tree 
as a predictive tool 
Luminescence antiClfA and 
antiMUC1 
The model created in the 
above test was used to predict 
luminescence values for 
antiClfA and antiMUC1 test 
sequences. In both cases, 
these predictions showed 
strong positive correlations 
with the experimental 
luminescence values that 
were statistically significant. 






In this study, a novel strategy has been developed to help visualize and score the overall 
performance of a test sequence (protein). Using machine learning and statistical analyses 
a mathematical model has been tested with significant prediction accuracy. The resultant, 
F2F bridge, is a combination of (i) a graphical overview predicting and displaying the 
strengths and weakness of a test sequence and (ii) an OP score that predicts and ranks the 
performances of different test sequences. Unlike the current in silico tools that inform the 
quality of only a single individual design parameter, F2F bridge provides a holistic view 
on a given test sequence. This top down approach of F2F bridge holds a key for informed 
protein design. F2F bridge could be deployed for both low throughput design and also for 
high throughput screening. In a low throughput setting, the F2F plot would play a pivotal 
role in highlighting the ‘pitfalls and merits’ of the design corresponding to a test sequence. 
The design could then be improved and F2F plot could be regenerated until satisfactory 
design is obtained. In a high throughput scenario, multiple designs of test sequences for 





Scale of use Outcome 
High Throughput A database of test sequences or extant 
proteins of known sequence can be 
queried with the F2F-bridge scoring 
each test sequence and identifying 
those most suitable. 
Low Throughput On a protein by protein basis the F2F-
bridge provides a graphical overview 
of the relationship between the 
features of the test sequence and the 
optimal values specified by the user, 
informing the user on how to improve 
the test sequence. 
 
Table 3.8: High throughput and low throughput applications of F2F-bridge. Depending 
on the intended application, F2F-bridge can be used as a tool to screen a large set of test 
variants by empirical ranking or for improving and fine tuning the existing design by 
graphically visualising the merits and falls of the model.   
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In both cases, F2F bridge is positioned precisely to bridge the gap between the myriad of 
seemingly abstract in silico values and wet lab performance. The simple graphical output 
and single OP score are easy to interpret with minimal know-how on programming. When 
combined with wet-lab testing, the patterns existing in the in silico data have been 
successfully used to generate predictive models. 
3.5.1 Relevance to the laboratory scientist 
The ultimate aim of F2F bridge is to bridge the increasing gap between the wet lab 
biologists and the powerful in silico tools. While scoring and ranking the test sequences 
based on their predicted overall performance, F2F bridge, mimics wet-lab screening and 
takes only a fraction of time, cost and expertise required in laboratory screening. This 
could lead to significant operational savings.  
Uses of F2F bridge could be divided into (i) wet lab scientists to study and analyse 
the merits and pitfalls of a protein visually using the F2F plot (ii) computational biologists 
for informed protein design using automated the redesign and (iii) protein based 
industries for screening lead candidates. 
3.5.2 F2F Bridge 
The blind F2F model (without feature selection, unsupervised and unweighted) showed 
promising results and an early indication of predicting the performance of a test sequence. 
This ‘unweighted and unsupervised’ combination of in silico parameters deemed to have 
an effect on overall biological performance of the test sequences. Wet lab 
experimentations are labor and time intensive and it is not cost effective to synthesize and 
test multiple test sequences. Given the ease of implementation, information provided by 
F2F bridge prior to synthesis is extremely valuable. The OP-score and the accompanying 
F2F plot highlight the design aspects that diverge from the user requirements and provide 
caution before wet lab synthesis. The blind model of F2F could be considerably improved 
with a larger dataset. In the meantime, feature selection and model refinement using 
machine learning methods has been implemented.  
As discussed earlier the blind folded model does not account for big players. 
However, proteins are multifunctional molecules and for every user defined overall 
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function, a set of in silico parameters would have a bigger influence than others. Thus 
identifying such big players becomes crucial to improve the accuracy of prediction. The 
ultimate goal of deploying the machine learning methods was to search for underlying 
patterns that could help predict the overall performance of the test sequence. 
3.5.3 Lasso driven feature selection and linear models 
Initially, feature selection was done using Lasso regression to predict the luminescence 
due binding of the test sequence to its target. In the L1 norm vs coefficients plot, the point 
at which the predictive feature enters the model and the effect it has on the test variable is 
very important. Although, big players that affect the bound luminescence were 
successfully identified, it was impossible to incorporate them into a linear model with 
statistical significance. As discussed earlier, the small nature of the current database and 
too many variables in wet lab processes (such as protein expression, binding to target, 
luminescence etc) were the two main bottlenecks. For this reason and the chance to utilise 
the increase in sample size, luminescence data from secretion was analysed. In this case, 
both anti-ClfA and anti-MUC1 datasets could be pooled together. This approach proved 
to be more successful in terms of improving the prediction accuracy of F2F bridge.  
Lasso regression based feature selection was performed again on secreted 
luminescence as a test variable to explore for patterns between the in silico parameters 
and experimental secreted luminescence. As expected this was more effective than the 
bound luminescence as test variable. It has been also shown that the linear model can be 
predicted using this method and a strong correlation was observed between the predicted 
and experimental test variable values. Once the linear relationship model has been 
established for anti-ClfA, this was used to successfully predict the test variable (secreted 
luminescence values) of antiMUC1 test sequences. The predicted luminescence values 
correlated with experimental luminescence values with good correlation. The antiMUC1 
experimental luminescence data originated from a different experiment and they are also 
a different class of proteins when compared to anti-ClfA set. The fact that the lasso 
directed model displayed strong predictive power in-spite of all the differences between 
the two groups, is very encouraging. 
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3.5.4 Random forest regression tree directed model 
Random forest regression tree model was used on ‘luminescence due to secretion’ as a 
test variable. The model was successfully able to explain over 41 % of the variability in 
the experimental secreted luminescence in the anti-ClfA test sequences. The regression 
tree model predicted test variable values closely correlated with the wet lab experimental 
values of the test variable. As observed with Lasso regression model, it was highly 
encouraging that the random forest regression model trained on anti-ClfA test sequences 
was also able to predict the values of test variable for the anti-MUC1 test sequences with 
significant correlation with the experimental values of secreted luminescence. 
3.5.5 F2F bridge - Foundation for overall performance prediction and hurdles 
ahead 
Using machine learning approaches such as Lasso regression model and the Random 
Forest regression tree model, F2F showed promising prospects for predicting the overall 
performance of a test sequence. The workflow and implementation of the prediction 
model is straightforward computationally but not on the wet lab experimentation. 
Synthesis/expression, functional assays and quality assessments on proteins is time 
consuming and is capital intensive. This results in small size of dedicated datasets. Using 
datasets from multiple sources is also challenging due to the vast variability in wet lab 
experimentation. Although this seems as a big challenge, recent advancements in 
synthetic biology provides an inspiring platform for high throughput synthesis and testing 
of multiple proteins. The current version of F2F lays the foundation for protein 
performance prediction using in silico tools. In the future, with an expanded dataset, the 
current two models would be re-assessed to confirm the increase in significance in 
prediction.  
 The current model also relies on web servers and third party tools for 
assessing in silico parameters of a test sequence. This also means that the accuracy of the 
individual in silico parameter values depends on the corresponding tools developed by 
various sources. In a future version, the accuracy of every individual web server/tool 
would be taken into consideration to provide an overall confidence score on the predicted 
performance. This would prevent error-compounding. 
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3.5.6 Outlook and F2F Bridge V.2.0 
In the current version of F2F bridge, it has been shown that the patterns observed in the 
in silico parameters of proteins could be used to predict significantly accurate overall 
biological performance and this could play a pivotal role in design optimisation and high 
throughput screening. Larger datasets could immensely benefit F2F bridge to improve in 
accuracy. Therefore this raises the need for the establishment of a new community wide 
data reporting system for in silico and wet lab data for proteins. This provides larger 
training datasets and wide variety of overall biological functions. SourceTracker 
algorithm used in metagenomic studies which is used to track possible sources of 
contamination in HTS studies served as standing example and inspiration for the proposed 
community wide data reporting system. Also, the regulation proposed by journals to 
deposit structures in PDB prior/after publication provide confidence to the establishment 
of such a data reporting system. F2F V2.0 would also have a parallel server which would 
take amino acid sequence as an input and perform all the in silico parameter calculations 
in-house. All the individual errors and compound errors will be taken into consideration 
and users would be informed with a graphical score. New strategies with applied weights 
to in silico parameters, combinational approach (performing multiple machine learning 
analyses sequentially for refinement) and suggestion nudges to improve the OP score will 
be incorporated.  
With all the above features F2F bridge forms a novel tool for informed protein 





The design model build test approach promoted by modern synthetic biology stands to 
benefit immensely from F2F bridge. This becomes an indispensable strategy for a 
biologist to triage the potential best performers and visualise the merits and falls of the 
protein. With little further adjustments in V.20 F2F bridge integrates in the DMBT cycle 
and adds the ‘learn’ step by empowering the end-user (wet lab biologist) with a holistic 
view on the overall performance of a protein. With a community-based data reporting 
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Background Recent advancements in life sciences such as protein engineering place 
biomedical research in fast and fascinating transformation phase. Translating such novel 
scientific concepts into a clinical setting requires extensive prior laboratory testing. The 
lack of efficient methods to track the performance of the therapeutics/diagnostics in vivo 
is a significant barrier and causing hindering their clinical translation. Bioluminescence 
imaging  for is an attractive imaging modality for in vivo applications. Targeted synthetic 
proteins equipped with an optical reporter such as a luciferase could become a valuable 
tool for in vivo optical imaging.  
Aims The aim of this study was to develop a novel in vivo imaging strategy using 
in silico engineered targeted synthetic luciferase proteins. 
Methods  In this work, test constructs targeting tumour associated MUC1 were built 
and tested for their in vitro binding to MUC1 antigen-expressing cell lines. Based on the 
luminescence readouts, the best performer was identified. This, as well as the best 
performer targeting S. aureus ClfA (from Chapter 2), were tested for specific imaging of 
target cells in in vivo murine models. 
Results Over 100 different multi-part test constructs targeted to human MUC1 
were modelled and validated using various computational tools to inform and guide 
downstream wet-lab experiments, as per Chapter 2. Gaussia luciferase (Gluc) or nanoluc 
were used as a luminescence reporters. All test construct variants were subjected to 
computational screening of predicted functionality. The best predicted performers were 
appropriately modified to ensure required hydrophobicity, net surface charge, active site 
exposure and valid 3D structure. Wet-lab studies were conducted to validate MUC1 
protein production and functioning (luminescence and specific target binding) in vitro.  
 For both MUC1 and ClfA targeted proteins, in vivo luminescence imaging 
studies involving systemic intravenous (IV) administration of proteins, validated synthetic 
protein specific accumulation at target cell locations within mice as evidenced by 
localised luminescence. Dose response studies indicated that luminescence output was 
both target cell and administered protein quantity related. Upon validation that 
systemically-administered synthetic proteins functioned as in vivo imaging agents, it was 
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investigated if these proteins could be produced by the mouse in vivo to achieve the same 
effect. In vivo transfection of quadriceps with DNA constructs used for synthetic protein 
production was examined using electroporation and lipofection. However, this DNA 
strategy proved unsuccessful.  
Conclusion  This study serves as a proof-of-concept for using targeted reporter proteins 




Recent advances in life sciences such as gene-editing [1], protein engineering and the 
advent of de novo designed proteins [2], place biomedical research in a fast and 
fascinating transformation phase. Translating such novel scientific concepts into a clinical 
setting requires extensive prior laboratory testing. Traditional laboratory testing methods 
are time consuming, invasive and involve multiple samplings, and have high associated 
costs for instrumentation and analysis. The lack of efficient methods to track the 
performance of the therapeutics/diagnostics in vivo is a significant barrier and causing 
hindrance towards their clinical translation [3].  
Testing novel diagnostic and therapeutic strategies requires real-time in vivo 
targeting, tracking and monitoring of various biological events that result due to the 
intervention. Such real-time in vivo tracking is pivotal in understanding complex cellular 
and systemic functions inside a test subject’s body. Optical imaging (OI) represents a 
simple low-cost solution for real-time in vivo monitoring and has contributed significantly 
to biomedical research [4]. Considering the inexpensive nature of OI and its ability to be 
applied for high-throughput work, OI is an attractive ionising radiation independent 
imaging alternative [3]. 
 
4.2.1 Bioluminescence in vivo imaging 
BioLuminescence Imaging (BLI) is an attractive imaging modality for in vivo research 
applications [5, 6]. BLI has a standout advantage when it comes to signal-to-noise ratios. 
This is due to the negligible background noise when compared to the luminescence signal 
from the luciferase reaction [7]. Due to the excitation-independent mechanism of 
luciferases, BLI does not face risks such as photobleaching and phototoxicity which are a 
major concern in other optical imaging modalities [7]. These properties make BLI highly 
suitable for in vivo imaging. As discussed in Chapter 2, Gluc, Rluc and Fluc are the most 
widely used luciferases for BLI. Engineered versions of synthetic proteins with luciferase 
parts have been proven as an attractive imaging strategy [6, 8-12]. However, BLI has faces 
challenges such as limited depth light penetration due to tissue absorption and scattering. 
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BLI using synthetic protein also raises questions such as potential for immunogenicity, 
toxicity and clearance from the system, that act as hurdles to clinical development.  
4.2.2 Synthetic proteins for in vivo imaging 
The number of engineered proteins used in imaging and therapeutic applications has 
grown significantly in the last 10 years. Engineering synthetic proteins with multiple 
functions and their applications have been discussed in Chapter 2. In this chapter, I aimed 
to design synthetic proteins targeting cancer cells, and to assess their potential as in vivo 
imaging agents. MUC1 was chosen as a cancer cell target to test the strategy, along with 
the bacterial-targeted agent developed in Chapter 2. 
.  
4.2.3 Tumour associated MUC1 
MUCIN-1 (MUC1) is a transmembrane glycoprotein expressed in glandular and luminal 
epithelial cells of various tissues/organs. MUC1 is long string like structure (200-500 nm 
long) having a transmembrane and an extracellular domain [13] (Figure 4.1). Both 
domains are linked together by stable hydrogen bonds. In non-malignant cells, MUC1 
acts as a protective layer to underlying epithelia. Upregulation of MUC1 expression is 
associated with various epithelial cancers [14, 15]. This generated high interest to pursue 
MUC1 as an oncogenic molecule. MUC1 plays an important role in disease progression 
involving cancer cell proliferation, metastasis and angiogenesis. Tumour-associated 
MUC1 differs from MUC1 present on regular cells [15]. The extent of glycosylation is 
one of the major differences between MUC1 found on regular cells and cancer cells. 
MUC1 is a heavily glycosylated protein - however, many studies have shown that the 
MUC1 presented on cancer cells has significantly lower levels of glycosylation [14, 15]. 
From a therapeutic point-of-view, the loss of glycosylation exposes the protein backbone 
and provides scope for antibody binding. Many therapeutic strategies to target MUC1 take 
advantage of the exposed protein due to loss of glycosylation. Given the multifaceted 







Figure 4.1: Graphical representation of MUC1 structure and various important parts. 
The structure of MUC1 consists of a cytoplasmic tail and an extracellular domain. The 
two domains are linked together by strong hydrogen bonds. SEA (sea urchin sperm 
protein, enterokinase and agrin, a highly conserved 120 AA module) domain has a 





The present work seeks to extend the concept of design-model-build-test of synthetic 
proteins described in Chapter 2, to validate the in vivo functioning of the synthetic protein 
as an in vivo imaging agent using murine models. MUC1 was chosen as a test target due 
to its high surface expression. The in vivo imaging strategy was also validated using S1 
test constructs targeting ClfA. The workflow and proof-of-concept of using synthetic 




4.3 MATERIALS AND METHODS 
4.3.1 Overview of in silico design of synthetic proteins 
Synthetic proteins targeting hMUC1 contained multiple subparts similar to the synthetic 
proteins shown in Chapter 2. Over 100 different variants were made and manually 
screened for potential best performers. Following the successful functioning of the 
synthetic proteins in Chapter 2, similar subparts and design principles were used for all 
the test constructs. In silico tools described in Chapter 2 were used to make several 
iterations of each test variant. All the designed structures were validated until desired 
structural conformations were achieved. VH and VL domains of anti MUC1 ScFv clone 
C595 were used as the binding domain to target MUC1. The amino acid sequence and the 
structure for MUC1 antigen was obtained from RCSB PDB. The process workflow and 
methods are explained in the sections below. 
4.3.2 Computational tools used for in silico -aided design and validation 
All the computational methods followed the same workflow and analyses as shown in 
Chapter 2 section 2.3.2. 
4.3.2.1 Protein structure modeling 
Protein modelling was performed primarily using the I-Tasser protein modelling suite 
[16]. The test constructs were also modelled using Rosetta modelling suite to increase the 
prediction reliability [17, 18].  
4.3.2.2 Superimposing predicted models 
The models predicted by I-Tasser and Rosetta were superimposed onto each other and 
RMSD was calculated using R-algorithms, developed in-house at the Tangney lab. 
4.3.2.3 3D visualisation 
UCSF Chimera was used for all protein visualisation throughout this work [19]. Chimera 
was also used to visualise protein-protein interactions after protein docking which was 
carried in the later stages of this workflow. 
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4.3.2.4 Protein-protein interactions 
Protein-protein interactions were studied using protein docking. AutoDock Vina was used 
for protein docking [20]. All the bound conformations were visualised in UCSF Chimera 
to screen for conformations that bind at the active sites (epitope-paratope interaction).  
4.3.2.5 Theoretical structure validation 
Ramachandran plots (RC plots) were used to validate the theoretical stability of the 
modeled structures. This information could be used to verify the structural stability of the 
model to exist in a natural environment. 
4.3.2.6 Total hydrophobicity vs Surface hydrophobicity 
Surface hydrophobicity was mathematically calculated by identifying the residues which 
have over 40 % exposure. The hydrophobicity is then calculated for these surface residues 
using in-house R algorithms. 
4.3.2.7 Structural remodelling and affinity improvements 
Improvements to the backbones, linkers and single residue replacements required 
structural remodelling. This was performed using Rosetta package. In cases where the 
modification is very small, the specific region is remodelled instead of modelling the 
whole structure. 
 
4.3.3 Wet-lab experimentation methods 
4.3.3.1 DNA design  
Following the in silico validation of all the test sequence. The finalised constructs were 
reverse translated into their corresponding DNA sequences using backtranseq feature on 
EBI website (https://www.ebi.ac.uk/Tools/st/emboss_backtranseq/). Codon optimisation 
was performed using condonopt tool on IDT website (https://eu.idtdna.com/codonopt). 
The final constructs were obtained from Twist Bioscience company. NEB and 
SnapGene’s Gibson assembly simulators were used to design the homologous arms to 
facilitate Gibson assembly. Primers were designed using the tools mentioned in Chapter 





Primer name Sequence 












MUC1Dia4aREV  TCTCGATCCCTAGCGCAAT 
MUC14bFWD TATTGCGCTAGGGATCGAGA 
MUC1Dia5aREV  TGCCAGGACCCCAGTAATC 
MUC1Dia5bFWD TGATTACTGGGGTCCTGGCAC 
 
4.3.3.2 Plasmid scale-up 
OG176 plasmid (Oxford genetics) with Kanamycin resistance was chosen for producing 
the synthetic proteins. Plasmid scale-up was performed using the protocol described in 
Chapter 2 section 2.3.4. For plasmid extraction, overnight subcultures of the transformed 
bacteria are subjected through Monarch Plasmid miniprep kit (New England Biolabs) 
protocol.  
4.3.3.3 Restriction digestion 
Refer Chapter 2 section 2.3.5 for detailed methods 
4.3.3.4 Gibson Assembly 
Refer Chapter 2 section 2.3.6 for detailed methods 
4.3.3.5 Validating cloning using colony PCR and Sanger sequencing 
Refer Chapter 2 section 2.3.7 for detailed methods 
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4.3.3.6 In vitro transfection 
Refer Chapter 2 section 2.3.8 for detailed methods 
4.3.3.7 Binding assays  
MCF7 (hMUC1-positive) and B16 (hMUC1-negative) cell lines were used to test the 
binding of synthetic proteins. Cells at different concentrations were blocked with 5 % 
BSA for 2 h followed by incubation with supernatant containing each test construct. Cells 
were washed 3 times and resuspended in PBS. 10 µl of each sample is taken in triplicates 
into a corning 96 well white plate. 50 µl of Coelenterazine substrate was added to each 
well and luminescence was measured using Promega GloMax® 96 luminometer. 
4.3.4 In vivo methods 
All animal procedures were performed in accordance with Health Products Regulatory 
Authority (HPRA) ethical guidelines. The project protocols were approved by animal 
ethics committee at University College Cork and the HPRA. All procedures were 
performed with care and effort to minimise pain and suffering.  
4.3.4.1 Animals used in the study 
6-8-week-old female BALB/c mice (weighing about 20 grams) were used for the studies. 
The animals were obtained from Envigo, UK. All the animals were monitored on a regular 
basis throughout the experimental period.  
4.3.4.2 Bacterial administration to mice 
Subcultures of the overnight bacterial strains were made 6 hours before the experiment. 
Bacteria were grown until an appropriate OD as per CFU requirements. The cells were 
harvested by centrifugation (3000 rpm for 20 min) and were washed 3 times with PBS. 
Mice were anaesthetised with Isoflurane throughout the procedure. Both the quadriceps 
of the mice were shaved to enable better access to the muscle. The 50 µl diluted cultures 
were administered intramuscularly using a 29G needle syringe.  
4.3.4.3 Systemic administration of synthetic proteins 
50-100µl of the synthetic protein supernatant were administered to the mice via IV 
through the lateral tail vein. All IV injections were performed 20-30 min before substrate 
administration or imaging.  
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4.3.4.4 Non-invasive in vivo imaging 
The IVIS Lumina II Imaging system (Perkin Elmer) was used for bioluminescence 
imaging. All mice were kept under isoflurane-induced anaesthesia all through the imaging 
period. IVIS living image software was used for image visualisation and analysis.  
4.3.4.5 In vivo transfection 
Lipofection In vivo turbofect (Invitrogen, Thermofisher) was used for transfecting mouse 
quadriceps using lipofection. Manufacturer’s protocol was followed to formulate the 
composition.  
Electroporation: Nepagene 21 electroporator was used for this electroporation. 
Electroporation was carried out on the mouse quadriceps using a plate based electrode 
setup. The mice were anaesthetised using Ketamine (75 mg/kg) and Medetomidine: 
(1mg/kg) (IP injection). DNA was injected prior to electroporation (needle size range 
26G-30G) at a depth of approximately 5 mm with 50 µl of DNA suspension in water. The 





4.4.1 In silico validation and screening 
Detailed workflow of all the in silico methods and strategies used here, are described in 
Chapter 2, (section 2.4).  
4.4.1.1 Tumor Associated MUC1 antigen 
Tumour associated human MUCIN 1 (MUC1) was chosen as a target to test the imaging 
strategy as a proof-of-concept. The amino acid sequence for MUC1 was obtained from 
PDB and the 3D structure was modelled using I-Tasser. Various structurally important 
domains were highlighted using UCSF Chimera. The antigenic sequence PDTRPAP and 






Figure 4.2: 3D structure of MUC1. Potential binding site for various MUC1 targeting 
antibodies such as C595, is highlighted in the red box. The VNTR (Variable number 
tandem repeat) region is highlighted in blue and yellow. The VNTR region is a highly 
glycosylated and consists of 20 amino acid repeats. Yellow represents the hydrophilic 





4.4.1.2 Design elements and design rationale 
In silico strategies, as shown in Chapter 2, were used to design synthetic proteins for 
targeting cancer cells. The amino acid sequence for the binding domain was retrieved 
from a ScFv clone previously shown to be capable of binding the MUC1 antigen on 
human breast carcinoma tissues [21]. An outline of different parts of the synthetic protein 
is shown in Figure 4.3. 
 
 
Figure 4.3: Different subparts of the test construct. Test variants differ in the presence 
or absence of each subpart and their arrangement. A monobody (ScFv) version and a 
diabody version were chosen as two variants of T-Domain.  
 
Over 100 different test variants were designed and screened for best performers. After 
multiple iterations of redesign and remodelling, 8 different test constructs were selected 
for wet-lab testing. The 3D structure and the construct schematics of the selected ScFv 




Figure 4.4: 3D structure and the construct schematics of the selected ScFv and Diabody 
test variants. MD2 and MD6 lack the binding domain and were designed as internal 
negative control for binding. Constructs M1, M2, M3 and M4 represent the ScFv version 
and the constructs MD1, and MD3 represent the diabody format. 













Non-binding control with ST Non-binding control without ST 
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4.4.1.3 Protein-Protein Docking 
Protein docking was performed on all the test constructs to test the in silico binding 
affinity. MUC1 structure modelled by I-Tasser was used as the receptor. MUC1 is a large 
protein and performing full length docking was computationally-intensive. The VNTR 
region where C595 binds was selected and the docking was performed in this restricted 
region. Upon docking, 8 different potential binding conformations for each test construct 
were visualised using UCSF Chimer and the best conformation for each test construct was 
selected based on free energy. Figure 4.5 shows the monobody M3 bound to MUC1. The 
docking results and all the in silico data corresponding to the finalised test constructs are 






Figure 4.5: Test construct M3 (ScFv variant) bound to MUC1. The whole chain of 
MUC1 structure is shown on the left. The zoomed-in section shows the Hydrophilic 
PDTRPAP region (Epitope), where the synthetic protein bind. Both the structures shown 






















M1 0.04 20.45 84.3 44.787 59.888 -17.5 66 
M2 0.17 21.44 88.4 45.777 60 -18 53.3 
M3 0.08 18 83.5 44.888 58.888 -16.7 66.5 
M4 0.22 4 75.5 45.194 61.509 -13.4 83.46 
MD1 0.07 5.54 84.3 44.888 59.444 -17.4 66.5 
MD3 0.0014 19 87.3 45.274 64.960 -18.6 37.3 
MD2 0.16 19 89 45.333 65 -17.7 37.53 
MD6 0.077 21.29 86.9 47.777 65.555 -15.2 24.33 
Table 4.1: In silico data of selected test constructs, obtained from various computational 
tools. From left to right, C-score (confidence score) from I-Tasser, TM score (template 
modeling score) as agreement between Rosetta and I-Tasser models, RC score 
(Ramachandran plot score), solvent accessibility of the active site (paratope regions), 






4.4.2 Wet-lab experimentation 
General assay methods are described in Chapter 2, section 2.4.5. All assays were 
performed in triplicate. 
4.4.2.1 Validating protein production 
Following thorough in silico validation the selected test constructs were tested in wet-lab 
studies for their functioning. Transfected cell supernatant, containing test proteins, was 
collected 48 h post transfection and a series of luminescence assays have been conducted 
to test the protein production. Figure 4.6 shows the luminescence from all the selected 






Figure 4.6: Secretion of various test proteins. Relative luminescence units were 
correlated to concentration in mg/ml using a standard curve obtained from Gluc protein 
standards. MD2 and MD6 lack the T-domain and were used as internal controls. All 


















































4.4.2.2 In vitro binding to MUC1 
In vitro binding was confirmed by measuring and comparing luminescence signals after 
binding. MCF7 were chosen as the MUC1 positive cell line and B16 cell line was chosen 
as MUC1 negative cell line. The choice of cell lines was based on previous literature and 
data from human protein atlas and expression atlas [14, 22, 23]. Both the cells were treated 
with 10 µl of each test construct for 1 h, at room temperature. The cells were washed 3 
times using PBS and 10 µl of the sample is taken into a corning 96 well white plate. Bound 
luminescence from each test construct is plotted in Figure 4.7. No significant correlation 
was observed when ScFv variants and Diabody variants were placed into groups. It was 







Figure 4.7: Bound luminescence of test variants to MUC1. Luminescence after binding 
to MUC1 on MCF7 cells. 106 MCF7 cells were incubated with 10 µl of each test construct 
for 1 h. Test construct M1 emitted highest bound luminescence followed by M3. 
 
Figure 4.8 shows the bound luminescence per µg of synthetic protein. Luminescence 
emitted from each test construct (non-bound) was measured in parallel and bound 
luminescence normalised to ‘amount of synthetic protein added (in µg)’ was calculated 






























































































































Figure 4.8: Bound luminescence normalised to protein quantity. Test constructs M3 and 


















































































































Selectivity of the synthetic proteins towards MUC1 positive cell lines was calculated by 
calculating ratio between bound luminescence (per amount of protein added) from MCF7 
cells and B16 cells. Figure 4.9 shows the selectivity of all the test constructs per 1µg of 






Figure 4.9: Selectivity of the synthetic proteins towards MUC1 positive cell lines. M1 
and M2 showed highest selectivity followed by M4. All the other test constructs have 






















































4.4.2.3 Selecting the best suitable candidate 
The in vitro binding assays presented an interesting scenario while selecting for a best 
performing test construct. M1 showed the highest signal intensity, M3 showed the highest 
bound luminescence per amount of protein added, and M1 and M3 showed high 
selectivity. The test constructs are ranked in Table 4.2, based on each wet-lab binding 









M1 M3 M3 
M3 M4 M1 
M4 M1 M4 
MD1 M2 M2 
M2 MD3 MD1 
MD3 MD1 MD3 







Figure 4.10: Selecting the best suitable candidate. Signal intensity and selectivity were 





M1 presented the highest bound luminescence and high selectivity. For preliminary in 
vivo testing, high signal intensity and high selectivity stand as the most important factors 
(Figure 4.10). Based on this hypothesis, M1 was selected as the best suitable candidate 
for further studies and all the further emphasis was placed in M1. 
 
4.4.2.4 Dose response assays 
Dose response experiments were performed using two MCF7 and B16 cells. Three 
different concentrations (by volume) of the synthetic proteins and three cell 
concentrations were used. Cells were treated with each synthetic protein for 1 h, at room 
temperature. Cells were washed 3 times and resuspended in PBS. All the samples, in 
triplicate, were placed in a Corning 96-well white plate. Luminescence was measured 
after adding 50 µl of coelenterazine. Cell dose response and synthetic protein dose 
response using test construct M1 is shown in Figure 4.11. In both instances, the bound 







Figure 4.11: Cell and synthetic protein dose response of M1 (a) Cell dose response: 
0,104, 106 cells of both B16 and MCF7 cell lines were treated with 10 µl of M1. (b) 
Synthetic protein dose response: 0, 1 µl, 10 µl of M1 have been added to 106 cells of both 
the cell lines. As expected, the luminescence increased with the increase in number 





4.4.3 In vivo imaging 
Following successful in vitro validation, the synthetic proteins, targeting MUC1 and S. 
aureus ClfA, were tested in murine models. It should be noted that significant ‘trial and 
error’ optimisation was required to identify the appropriate time intervals for imaging, 
and multiple in vivo studies were performed in advance to optimise for the below shown 
studies (data not shown). 
 
4.4.3.1 In vivo synthetic protein dose response (M1) 
M1 in three different concentrations, was administered systemically by IV injection via 
lateral tail vein. In all cases, the synthetic proteins were diluted in PBS and reconstituted 
to a 100 µl volume. Subcutaneous injections of 107 MCF7 and B16 cells were given on 
each side of the mouse. 20 min after administering the cancer cells, 50 µl of coelenterazine 
was injected into the cell locations. Mice were anaesthetised with Isofluorane and were 






Figure 4.12: M1 dose response and target specificity in vivo: An increase in 
luminescence was observed with respect to the increase in synthetic protein 
concentration. Luminescence from left subcutaneous pocket, with MCF7 cells, produced 




4.4.3.2 In vivo cell dose response (M1) 
100 µl of M1 was administered intravenously via lateral tail vain to all the mice. Mice 
were injected subcutaneously with different concentrations of cancer cells (0, 105 and 
107cells). 20 min after administering the cancer cells, 50 µl of coelenterazine was injected 
into the cell locations. Mice were anaesthetised and subjected to imaging. All the 
experiments were performed in triplicate. 
 
Figure 4.13: In vivo cell dose response. An increase in luminescence was observed in 
relation to the increase in number of cells. Luminescence from left subcutaneous pocket, 




4.4.3.3 In vivo synthetic protein dose response (S1), S. aureus targeting synthetic 
protein 
S1 in three different concentrations, was administered systemically by IV injection via 
lateral tail vein. In all cases, the synthetic proteins were diluted in PBS and reconstituted 
to a 100 µl volume. Mice were anaesthetised and 107 S. aureus cells diluted in PBS (in 50 
µl) were administered intramuscularly on the left quadricep. 20 min after the IM injection, 
50 µl of coelenterazine was injected into both the quadriceps. Mice were anaesthetised 







Figure 4.14: S1 dose response in vivo 100 µl, 20 µl and 0 µl of S1 was administered 
systemically via tail vein. 107 S. aureus cells were injected (IM) on the left quadriceps of 




4.4.3.4 In vivo bacterial cell dose response (S1) 
100 µl of S1 was administered intravenously via lateral tail vein to all mice. Mice were 
anaesthetised with isoflurane and different concentrations of S. aureus cells (0, 105 and 
107 cells) diluted in PBS (in 50 µl) were administered intramuscularly to the left 
quadriceps. 20 min after administering the bacterial cells, 50 µl of coelenterazine was 
injected into the cell locations. Mice were anaesthetised and subjected to imaging (Figure 
4.15). A dose response was not evident in this case. While both 105 and 107 bacteria groups 
displayed higher luminescence than no bacteria, the 107 group did not produce higher 
luminescence than the 105 group. Furthermore, some off-target luminescence was 
observed in the right quadriceps of mice injected with 105 cells, perhaps due to basal level 





Figure 4.15: In vivo bacterial cell dose response study. 100 µl of S1 was administered 
systemically via tail vein. 0, 105 and 107 S. aureus cells were injected (IM) on the left 
quadriceps of mice. In this case the luminescence from 105 cells was slightly higher than 
luminescence from 107 cells (n=2). Some off-target luminescence was observed in the 




4.4.3.5 GlucS1 vs NanolucS1 
As discussed in Chapter 2, NanoLuc was deemed likely to have a significant advantage 
over Gluc for in vivo imaging. Previous literature shows that NanoLuc is brighter and has 
improved half-life over Gluc. To test this in vivo, 100 µl of GlucS1 and NanolucS1 were 
administered systemically to mice by IV injection via lateral tail vein. Mice were 
anaesthetised and 107 S. aureus cells diluted in PBS (in 50 µl) was administered 
intramuscularly to the right quadriceps. 20 min after IM injection, 50 µl of coelenterazine 
(GLuc) or furamazine (NanoLuc) was injected into both left and right quadriceps. Mice 
were anaesthetised and subjected to imaging. Mice were imaged for 2 h at various time 
points. Figure 4.16 shows the signal intensities of GlucS1 and NanoLuc S1 with respect 
to time. This study was performed in triplicate. NanoLucS1 was brighter than GlucS1 
throughout the experiment and produced a significantly higher signal even after 100 min 





Figure 4.16: GlucS1 vs NanoLucS1. 107 S. aureus cells were injected into the right 
quadripceps of mice. 100µl of test protein was injected via tail vein. NanoLucS1 (shown 






































4.4.4 In vivo production of synthetic proteins 
Following validation that systemically administered proteins function as imaging agents 
in vivo, it was investigated if these proteins could be produced by the mouse in vivo to 






Figure 4.17 Schematic of in vivo production of targeted synthetic proteins: The concept 
involves administration of plasmid DNA to mouse quadriceps to induce systemic 
production of the targeting luciferase. The systemically-circulating protein binds to the 




Quadriceps of mice were transfected using electroporation or lipofection with DNA 
encoding NanolucS1 or Fluc (as a control for transfection). After 72 h, 107 S. aureus cells 
were injected into the left quadriceps of mice. 100 µl of furamazine (NanoLuc) or luciferin 
(FLuc) was injected by IV via lateral tail vein. Mice were imaged after anaesthetising with 
isoflurane. For lipofection groups, no luminescence was observed in any mouse, including 
the FLuc transfection control group, indicating insufficient DNA transfection to produce 
luminescent protein (data not shown). This was repeated, producing the same result. 
For electroporation groups, high-level, quadriceps-localised luminescence was evident in 
the group transfected with Fluc, indicating successful DNA transfection and localised 
intracellular luminescent protein production (FLuc is not secreted). However, no 
luminescence was detected in any mice transfected with Nanoluc S1, either at the 
quadriceps site of transfection, or distally at target cell sites, indicating insufficient 





Figure 4.17: Transfection of mice quadriceps for in vivo protein production. (a) Right 
quadricep was electroporated with plasmid encoding Fluc. (b) Right quadricep was 
electroporated with plasmid encoding NanolucS1. No luminescence was observed in the 





While the in vivo production strategy proved unsuccessful in this study, it is possible that 






This work presents use of synthetic targeted proteins as an in vivo imaging strategy. Two 
different targets, MUC1 and ClfA, were chosen for the study. However, the in silico 
strategies described could be adopted for various other targets. Synthetic proteins were 
built to bind to hMUC1, using the in silico aided-design strategy described in Chapter 2. 
Design rationale and choice of subparts were adopted from Chapter 2, to have high 
resemblance. Over 100 different test variants were designed and modelled with the aim 
of obtaining the optimal structural conformations. The binding domain was built by 
incorporating minimal regions of C595 ScFv. Immense care was taken to ensure 
maximum exposure of the active sites. Over 10 different linker type and size combinations 
were sampled. Designing a diabody format required additional care while choosing 
linkers due to its bigger size. Gluc was chosen as the imaging part due to its small size 
and, due to its ATP-independence, ability to function outside the cellular environment 
where ATP is scarce.  
In vitro testing was carried out to validate secretion and functioning (binding and 
luminescence) of the synthetic proteins. Throughout the work, luminescence was used to 
inform the protein production, binding and selectivity. The goal of the in vitro assays was 
to find a best suitable candidate for use in in vivo imaging. The bound-luminescence data 
presented a challenging and interesting case while selecting for the best candidate. M1 
showed the highest luminescence per volume, M3 showed highest luminescence per 
protein weight and M1 and M3 showed similar selectivity for the target. Solving this issue 
required the application of ‘optimal performer’ logic that was described in Chapter 2. 
Detecting bound-luminescence in vivo requires high selectivity for the targeted cells. M1 
and M3 both showed appreciable selectivity. Luminescence per volume of M3 was 
noticeably lower than M1. The low signal intensity of M3 would play a detrimental role 
for the overall goal (balance between high signal and high target binding). This solidified 
the argument of selecting of M1 over M3. The optimal performer logic helped to guide 
the screening process based on the user-defined overall function. In future, adding 
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arbitrary values to the coefficients of S, N and I, would provide an empirical basis while 
screening for the best performer.  
The in vitro studies provided a preliminary understanding of the basic functioning 
of the protein. However, questions regarding the structural integrity and stability would 
have been answered through more wet-lab validation. In this context, Western blots were 
performed using anti-Flag antibodies, as per Chapter 5. However, after multiple attempts 
with both ClfA and MUC1 proteins, this was unsuccessful (data not shown). These data 
would have been beneficial to confirm the size, integrity and concentration of the 
synthetic proteins. Similar anti-Flag Western blots were readily performed in Chapter 5 
to show the size and validate protein production. The failure to detect synthetic proteins 
on Western blots could be due to some features unique to these synthetic proteins.   
The ability of the synthetic protein to circulate systemically throughout the body 
and localise to a specific target to produce an imageable luminescence signal acts as a 
proof-of-concept for in silico aided synthetic protein design of targeted proteins for in 
vivo use (therapeutic, imaging etc). In vivo studies using systemically-administered M1-
Gluc indicated localisation of this protein to target cells. In this study, +/- MUC1 cell lines 
(MCF7 and B16) instead of solid tumor models due to quick turnover time of experiments. 
However, significant ‘trial and error’ optimisation was required to identify the appropriate 
time intervals for imaging. Although the synthetic proteins displayed strong localisation, 
in the case of S1, use of off-target cells would have further validated the target-specific 
binding. Further assays such as FACS would also reconfirm the binding. In both the in 
vivo studies using M1 and S1, administering the mice with a non-targeting binding 
antibody would have been beneficial to rule out the chances of accidental accumulation. 
Further, using solid tumor models and a complete dose response experiments showing the 
signal saturation would solidify the confirmation of binding. As the study proceeded, it 
was determined that the short in vivo half-life of the Gluc-colanterizine system may 
represent a limiting factor in performing these studies. Literature on Nanoluc guided 
towards testing of Nanoluc and its substrate as the imaging subpart in one of the test 
constructs. In Chapter 2, a variant of S1 with Nanoluc was designed and tested in vitro. 
These assays didn’t show any noticeable in vitro advantage when Gluc was replaced with 
Nanoluc. However, in vivo, the NanolucS1 construct showed a significant improvement 
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in signal intensity (Figure 4.16). It is to be noted that both Coelenterazine and Furamazine 
have been tested as a substrate against NanolucS1 and in this study Coelenterazine was 
shown to be brighter when compared to Furamazine. 
Following the findings that systemic administration of Nanoluc S1 validated the 
functioning of the synthetic proteins as in vivo imaging agents, studies were conducted to 
investigate if these proteins could be produced by the mouse in vivo to achieve the same 
effect. Transfecting quadriceps muscle was hypothesised to serve as a continuous protein 
producing reservoir [24] (Figure 4.17). This in vivo production strategy proved 
unsuccessful in this study. This could be due to a number of reasons such as (i) low protein 
production, (ii) poor secretion, (iii) immune response to sustained protein production etc. 
With further studies on the in vivo properties of the synthetic proteins and optimising 
design parameters, it might be possible to bring this concept to reality. In this study, 
plasmid with a moderate strength constitutive promoter has been used. Moderate strength 
plasmid was chosen to avoid the chance of toxicity of the produced protein. Considering 
the failure to obtain a signal from the transfected quadricep as well, further experiments 
using plasmids with stronger promoters could be explored. 
Systemic administration of the various synthetic proteins showed no toxic or any 
adverse reaction during this study. Ethical constraints at the time of experiments directed 
towards the use of BalbC instead of nude mice. Although the successful in vivo targeting 
and imaging validated the original intended function, further experiments are required to 
test the pharmacokinetics, pharmacodynamics and long-term toxicity of the synthetic 
proteins. For instance, in silico tools could be used to identify and eliminate commonly 
found immunogenic motifs from the designed construct. In vitro synthesis in vivo testing 
of multiple test variants would be useful to find the least immunogenic candidate.  
Throughout the study, mathematical and computational approaches were used at 
various stages of design, model, build and test. Including the concept of Function2Form 
bridge, detailed in Chapter 3, the data from the wet-lab studies could be used to train the 
machine learning models of F2F bridge. This adds the learn step to the ‘design-model-
build-test’ approach of modern synthetic biology. However, predicting in vivo 
performance requires additional data from murine models such as their pharmacokinetics, 
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pharmacodynamics, immunogenicity and various assays facilitating the translation of the 
in vivo work to clinical stage.  
In future, F2F bridge would be an integral component in in silico aided design and 





In this study, multiple variants of synthetic proteins targeted to human MUC1 were 
modelled and validated using various computational tools to inform and guide 
downstream wet-lab experiments, as per Chapter 2. Wet-lab studies were conducted to 
validate MUC1 protein production and functioning (luminescence and specific target 
binding) in vitro. For both MUC1 and ClfA targeted proteins, in vivo luminescence 
imaging studies involving systemic intravenous (IV) administration of proteins, validated 
synthetic protein specific accumulation at target cell locations within mice as evidenced 
by localised luminescence. This study serves as a proof-of-concept for using targeted 
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Background Self-assembling protein cages are abundant in nature. Viruses, bacterial 
microcompartments, ferritins and heat shock proteins are some examples of these highly 
organised protein structures. The spontaneous assembling and disassembling of such 
proteins presents promising applications in targeted release and encapsulation of drugs. 
Assembly mechanics of these self-assembling proteins rely on the composition of their 
interactive protein interfaces. Engineering protein interfaces helps to understand protein 
interactions and aid real-time monitoring of spontaneous self-assembly to visualise the 
encapsulation and release mechanics.  
Aims The aim of this work was to (i) use in silico methods to engineer self-assembling 
monomers and (ii) to develop a wet lab method to validate the self-assembly using 
fluorescence. 
Methods For in silico-aided protein design, computational tools such as I-TASSER and 
Rosetta were used for 3D structure modeling and UCSF Chimera for protein visualisation 
and identifying appropriate cysteine insertion locations to enable employment of a 
FLAsH-EDT2 fluorescence assay to report peptide interaction. DNA constructs were 
generated for protein production in E. coli. Protein production was confirmed by Western 
blot. Self-assembly was examined using a whole-cell fluorescence assay.  
Results All proteins were successfully produced and confirmed by Western Blot. Whole-
cell fluorescence assays provided the evidence that supports the interaction between 
FlAsH-EDT2 and the engineered bi-partite cysteine residues, indicating oligomerisation 
of monomer proteins. 
Conclusion In this work, proof-of-concept of a novel method to visualise self-assembly 
is introduced, by computationally inserting bi-partite cysteine residues at the protein 





5.2.1 Interface design and potential applications of self-assembly 
Proteins are multifunctional building blocks of life, that play various fundamental 
functions in all living organisms. Naturally existing proteins are involved in various 
biological functions such as regulatory and sensory functions, immune responses, 
mobility and structural stability [1, 2]. The ability of these biomolecules to assemble into 
multiple conformational variants and possess interactive interfaces, provides for their 
multifunctional nature [3]. In some higher order interactions, protein monomers self-
assemble into large oligomeric complexes, giving rise to unique structural cage-like 
complexes. Comprehending the complexity of biological design and redesigning it into 
reliable, predictable and useful system is an underlying aim of modern-day synthetic 
biology. Naturally occurring proteins represent only a tiny fraction of the mathematically 
possible protein canvas and natural proteins are poorly spread in the total sequence space.  
The introduction of de novo principles to protein design provides the opportunity to 
explore countless novel structures outside the realms of natural evolutionary constraints 
[4]. Unlike protein structure prediction, where computational methods predict the possible 
3D structures corresponding to a sequence of amino acids, de novo protein design predicts 
a sequence that folds into a user defined 3D structure. With the rise in de novo designed 
proteins, self-assembly is gaining new interests and forms a powerful blueprint for 
bottom-up design of various synthetic proteins for a wide range of applications such as 
bio-therapeutics, protein-based diagnostics, biosensing and biomaterials [4, 5].  
Intermolecular forces such as hydrophobic interactions, hydrogen bonding and ion pairing 
etc, are the key players for protein self-assembly. These forces when combined with 
structural complementarity at the interface of an interacting protein generate molecular 
complexes [6]. Most biological systems rely on these protein-protein interactions in order 
to carry out various cellular functions. Thus, understanding the fundamentals of protein-
protein interactions (PPIs) is the first step for creating artificial protein complexes [7]. In 
recent years, significant scientific interest in protein engineering has been focusing on 




5.2.2 Computational protein-protein interaction design 
Achieving desired affinity at a precise location and specificity is still under research and 
no single method to date can design an interacting interface with total accuracy. 
Knowledge-based methods and protein docking assembly are two mainly used principles 
in designing protein-protein interactions. In most cases, a combination of both sequence 
design and protein docking algorithms are used to identify structures and sequences that 
promote binding with further optimisation [7]. 
5.2.2.1 Knowledge based methods vs protein docking/assembly 
Knowledge-based methods rely on existing experimental data and statistical modes to 
extract and interpret the patterns in the given protein structures. These homology based, 
data driven methods map the interfacial residues and commonly found structures onto the 
structure and composition of the query protein to predict binding [9]. Hot spot centric 
design is the most commonly used approach for designing new interfaces from the 
homology driven statistical models. In this approach, the hot-spot residues occurring on 
the naturally existing protein complexes are grafted on the target interface. This is 
followed by computational optimisation to optimise for steric hindrance and side chain 
optimisation [7]. 
Docking based approaches use 3D models to search for conformations with high surface 
complementarity and low free energy [9]. This method is also referred to as “dock and 
optimisation” [10]. The predicted interface with lowest energy is first established by 
computationally comparing the free energy changes at all possible conformations. In most 
cases the structures and the interface composition are refined to achieve ideal binding 
efficiencies[7]. 
Although both these methods differ in their core principles and approaches, they can be 





5.2.3 Understanding protein cages  
Protein cages can be defined as hollow, three-dimensional oligomeric protein structures 
built from self-assembly of constituent monomers. This hollow cage like structure gives 
them the potential to encapsulate and control the release of a molecule of interest by 
genetic or chemical conjugation [11]. Protein cages are highly organised structures and 
are abundantly found in nature. Viral capsids, bacterial microcompartments, HSPs and 
ferritins are a few examples. Ion storage, catalysis and packing nucleic acids are some 
common roles of protein cages [12]. Naturally existing protein cages acts as a structural 
and functional guide for the development of synthetic protein cages. Their ability to 
spontaneously self-assemble has driven the ideas tailoring novel synthetic cages, with 
novel functional architectures, for biosensing and targeted therapeutic release. 
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Table 5.1: Engineered Protein Cages for Biomedical Applications 
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5.2.3.1 Assembly mechanics and encapsulation kinetics 
In nature, assembly mechanisms can be broadly divided into two main types based on 
whether or not they need cargo intervention for self-assembly [24]. In those cases 
which assemble without any cargo, the self-assembly relies on subunit-subunit 
interactions. This type of assembly construction initiates with nucleation and growth 
[25]. Cargo independent assemblies could be found in cowpea chlorotic mottle virus 
(CCMV). While, the cages that need cargo for self-assembly rely on scaffolding 
proteins and packing machinery. In such cases, the assembly is achieved by 
electrostatic interactions between the monomers proteins and negatively charged 
DNA/RNA [25]. Post assembly encapsulation is commonly achieved either by post 
cage by loading the cargo through environmental changes (such as pH or temperature) 
or by electrostatic interactions. Cargo can also be encapsulated during the cage 
assembly by molecular recognition in which the cargo is attached to the proteins by 
structural/electrostatic linking.  
5.2.4 Visualising self-assembly 
While design and synthesis of self-assembling protein cages has been well 
documented, the visualisation of the cage architectures remains expensive. This often 
relies on physical methods such as Cryo-EM, NMR or X-ray crystallography. 
Although these methods help visualise the final 3D conformation of the assembly, the 
costs and efforts associated with them are high. In recent years, protein assemblies and 
protein interactions were monitored by labelling the proteins with appropriate optical 
tags. The optical readout (Fluorescence/luminescence/colorimetric readouts) from 
these proteins is analysed using an end-point assay. Such an end-point analysis assay 
would not effectively monitor the process of self-assembly and has too many 
experimental variables.  
FlAsH-EDT2 is an organoarsenic compound used in bioanalytical research as a 
fluorescence reporter for tagging various proteins in cells. The structure of FlAsH-
EDT2 contains 1,3,2-dithiarsolane substituents on a fluorescein core. FlAsH-EDT2 
becomes fluorescent upon binding to proximal tetra-cysteines. FlAsH on its own is 
non-fluorescent when bound to EDT2. When FlAsH-EDT2 binds to a tetra-cysteine 
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motif, EDT2 is displaced and the compound becomes highly fluorescent. Due to its 
small size and membrane permeability, it has unique advantages over existing protein-
based fluorescent tags. 
In this work, bi-partite cysteine residues were computationally engineered into protein 
cage self-assembly interfaces and a FlaSH-EDT2 based fluorescence strategy was 
developed to visualise self-assembly and continuously monitor the protein-protein 
interactions. During self-assembly, the proximity of the bi-partite cysteines initiates 
the FlAsH-EDT2 labelling which produces a fluorescence readout. This fluorescence 
readout indirectly indicates the protein-protein interaction. This addition of the bi-
partite cysteine residues and FlaSH-EDT2 mediated fluorescence strategy provided 




5.3 MATERIALS AND METHODS 
5.3.1 In silico experimental methods 
5.3.1.1 Design overview 
Previous literature on self-assembling cages acted as a starting point for proof-of-
concept and to validate the FlAsH-EDT2 based visualisation strategy. An existing 
cage strategy from Padilla et al [21] was adopted for the symmetry driven self-
assembly (Figure 5.2). A dimeric subunit and a trimeric subunit were linked together 
with a rigid 9 amino acid helical linker to form a megamonomer. Oligomerisation is 
achieved when the dimeric subunit and the trimeric subunits find their identical copies 






Figure 5.2: Cage self-assembly model. Illustration adapted from Padilla et al (2001) 
[21]. The dimeric and trimeric subunits were linked together with a helical linker. The 
resultant Mega Monomer (cage protein) spontaneously assembles into a cage like 





5.3.1.2 Construct design 
For testing the proposed bi-partite cysteine insertion, the first step was to find 
monomers capable of self-assembly. In this context, protein subunits PDB ID 1AA7 
(dimer subunit) and 1BRO (trimer subunit) were chosen based on previous literature 
on self-assembly and their stability. The 9 amino acid helical linker KALEAQKQK 
was chosen based on the literature [21]. 
5.3.1.3 In silico tools used for design, modeling and validation 
Table 5.2 lists the in silico tools used for designing assemblies with cysteine inserts. 
Tool Purpose 
Rosetta suite Redesign and modeling 
I-Tasser [26] Protein modeling 
R-package and in-house algorithms Evaluating conformational integrity and 
measuring agreement between models 
using RMSD scoring. 
COACH (web server) Active site prediction 
PROCHECK web server Generating Ramachandran plot 
Chimera [27] Protein 3D visualisation 
Table 5.2: In silico tools used for computationally inserting cysteine residues and 
validating protein models. 
 
5.3.1.4 DNA design and synthesis 
The final amino acid sequences, after a thorough in silico validation, were reverse 
translated into their corresponding DNA sequences. The DNA sequences were codon 
optimised for E. coli BL21 using the codon optimisation tool available on IDT website 
(https://eu.idtdna.com/codonopt). NEB and SnapGene’s Gibson assembly simulators 
were used to design the homologous arms to facilitate Gibson assembly. Amplification 
and sequencing primers were designed using Benchling’s primer design tool. The 
216 
 
primers were cross verified using Primer3Plus. All construct DNA sequences and 
primers were sourced from Integrated DNA Technologies.  
Primer Name Sequence 
1AA7 FWD actttaataaggagatatacATGCAGAAATTATTGACAGAGGTTG 
1AA7 RVS tgctcagcggtggcagcagcTTATTTATCGTCATCATCTTTGTAATCT 
IBRO FWD actttaataaggagatatacATGCCTTTTATCACAGTTGGG 
IBRO RVS tgctcagcggtggcagcagcTTATTTATCGTCATCGTCTTTGTAATC 
Cage FWD actttaataaggagatatacATGCCTTTTATAACAGTCGGGC 
Cage RVS tgctcagcggtggcagcagcTTATTTATCGTCGTCGTCTTTGTA 
Gaussia FWD actttaataaggagatataccATGATGGAAGCCAAACCC 







Table 5.3: Sequences of all amplification and sequencing primers used. 
 
5.3.2 Wet-lab methods  
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5.3.2.1 Plasmid amplification and extraction 
pRSFduet-1 (Novagen) dual expression vector with Kanamycin resistance was used 
for protein expression. E. coli BL21 was used for plasmid amplification. E. coli BL21 
cells were made competent using Cohen et al. 1972 protocol. 100 ng plasmid DNA 
was mixed with 30 µl competent cells and placed on ice for 20 min. The suspension 
was subjected to heat shock at 42 ◦C for 20 min. The cells were placed in ice for 2 min 
and 1 ml LB broth added. 100 µl transformed cells were plated on LB agar containing 
50 ug/ml Kanamycin. Colonies were then subcultured and stored in -80 ◦C for further 
use. For plasmid extraction, overnight subcultures of the transformed bacteria were 
subjected to the Monarch Plasmid miniprep kit (New England Biolabs) protocol. The 
extracted DNA was stored at -20 ◦C in situations where it wasn’t used immediately.  
5.3.2.2 Restriction digestion 
pRSFduet-1 was digested by restriction enzymes Nco1 and AvrII with CutSmart 
reaction buffer (NEB) at 37 ◦C for 1 h. The manufacturer’s protocol was followed to 
adjust the reaction volumes as per the need. Following the restriction digest, the DNA 
was purified using the PCR purification kit (Qiagen) protocol. In all cases, the 
restriction digest was verified by Agarose gel electrophoresis and the DNA 
concentration was determined using NanoDrop (Thermofisher). 
5.3.2.3 Gibson Assembly 
Gibson Assembly was carried out using the Gibson Assembly master mix described 
by DG Gibson et al (2009). The plasmid and DNA gene blocks were mixed in 1:3 
ratio in a Gibson Assembly master mix and incubated at 50 ◦C. E. coli BL21 cells were 
transformed with the assembled plasmids and plated on LB agar medium containing 
the appropriate antibiotic. Gibson Assembly was confirmed by colony PCR and sanger 
sequencing.  
5.3.2.4 Validating cloning using colony PCR and Sanger sequencing 
The selected colonies were added to NEB PCR master mix with 2.5 µl of 
corresponding primers. PCR was carried out as per NEB Q5 polymerase PCR 
protocol. Sanger sequencing (GATC light-run) was also performed by GATC 
(Eurofinsgenomics) on the selected colonies to validate assembly. 
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5.3.2.5 Inducing protein expression 
Transformed cells were suspended in 20 mL LB broth containing 30 mg/mL 
Kanamycin. 1:500 sub cultures were made from the overnight stock and grown to 0.6 
OD600. The subcultures were induced with 0.5 mM Isopropyl ß-D-thiogalactoside 
(IPTG) left overnight in a shaking incubator at 25 ˚C. Cells were harvested by 
centrifugation at 4000 rpm for 20 min and were subjected to lysis. BugBuster lysis 
buffer, supplemented with Lysonase reagent (Novagen) and a cocktail of protease 
inhibitors (cOmplete) was used for cell lysis. Lysis was carried out at room 
temperature for 20 min. The lysate was then clarified by centrifuging at 10,000 rpm 
for 20 min at 4 ˚C. 
 
5.3.2.6 Analysing protein expression 
Total protein concentration was determined by standard Bradford assay. Protein 
standards were prepared using 1 mg/ml Bovine Serum Albumin. 200 µl of Protein 
Assay Reagent (Bio-Rad) was used for the analysis. BSA standards were made from 
0-60 ug/ul. 1 µl test protein sample was mixed with 799 µl MilliQ water and 200 µl 
Protein Assay Reagent (Bio-Rad). Samples were loaded onto a 96 well plate and 
absorbance was measured using a FLUOstar OMEGA (BMG) plate reader.  
To validate protein expression, Coomassie blue staining was performed on all 
samples. 1 mg of lysate was diluted with LDS (NuPAGE, Invitrogen) to form a 1X 
solution. The lysate was boiled for 5 min at 95 ◦C. 10-15 µl of the sample is loaded 
into a 4-10 % Bis-Tris gel (1 mm, 15 well) along with precision plus protein ladder 
(Bio-Rad) and electrophoresis was carried out at 100 V for 90 min. After the run 
completion, the gel was washed and fixed in 50 % methanol + 10 % acetic acid 
solution for 15 min. After subsequent washing with water, Coomassie blue (Eazy 
Blue, Bio-Rad) was added to gel and stained for 1 h. The gel was washed 3 times with 
water and results analysed using ImageLab 5.2.1 (Bio-Rad). 
For Western blotting, the electrophoresis was carried out as above and the proteins 
were transferred onto a nitrocellulose membrane (Bio-rad Midi) using rapid transfer 
for 7 min. The nitrocellulose membrane was blocked with Blocking Buffer PBS 
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(Odyssey) for 1 h and incubated overnight at 4 ˚C with anti-FLAG antibody (Sigma, 
F1804). After washing the membrane 3 times with TBST, the membrane was 
incubated with anti-mouse green secondary antibody for 1 h in the dark at room 
temperature. The membrane was scanned using LICOR Odyssey infrared imaging 
system and the image analysis was performed using Odyssey imaging software (LI-
COR). FLAG-BAP protein was used for standards to normalise protein concentrations 
for downstream experiments. The integrated intensity of the Western blot bands were 
used for relative quantification on the Li-Cor Odyssey software. 
5.3.2.7 Fluorescence assays and validating FlAsH binding. 
 
Binding assays with cell lysates. 600 µl of 0.5 mg/ml of lysate was incubated with 
FlAsH-EDT2 (0.1 µg) in the dark (FlAsH is photosensitive). Lysates were washed 
with PBS and transferred in triplicates to a black 96 well plate (Titude Vision plate). 
Fluorescence was measured on an Infinite M200 Multimode plate reader (TECAN). 
Fluorescence was also measured using the IVIS Lumina II Imaging system (Perkin 
Elmer) with filters, Ex 485nm and Em 535nm. Living image (Perkin Elmer) software 
and Microsoft excel were used for analysing the data.  
Binding assays using whole cells. 
Subculture cells were washed and resuspended in PBS and normalised to OD 0.3. Post 
washing, cells were incubated in FlAsH Buffer (100 mM Tris HCl, 100 mM NaCl, 1 
mM EDTA, 1 mM βME, pH 7.8) for 1 h at room temperature. 0.5 µg FlAsH-EDT2 
was added and the samples were incubated in the dark for 2 h. The unbound FlAsH-
EDT2 was removed by washing with FlAsH buffer for 3 times. The samples were 
loaded in triplicated into a black plate (Titude Vision plate) and read in triplicates 
using an Infinite M200 Multimode Plate reader. Microsoft excel was used for 





5.4.1 In silico design and modelling of self-assembling cage 
The amino acid sequences for the dimeric protein M1 matrix protein of influenza virus 
(PDB ID 1AA7) and the trimeric protein Bromoperoxidase (PDB ID code 1BRO) 
were fetched from PDB and a 9-residue helical linker was inserted to connect them 
together. The total protein was termed as MegaMonomer. The 3D structure was 
modelled using I-Tasser. This MegaMonomer would self-assemble into 12-mer, 550 
kDa protein cage. Insertion of sequences for cysteines was carried out using Rosetta 
design. The protein-protein interaction interface was identified for all necessary 





Figure 5.3: Protein construct map for the 3 oligomerization subunits. (a) Dimeric 
subunit with engineered cysteine residues. (b) Trimeric subunit with cysteine 
insertions. (c) MegaMonomer, showing the dimeric and trimeric subunits linked via a 




5.4.1.1 In silico validation of engineered cysteines 
For cysteine insertions, on all three proteins (Dimer, Trimer and the MegaMonomer) 
amino acids at the interface which are most energetically favourable and minimal 
structural importance were identified to ensure structural integrity. The dimeric 
protein assembles in a head-tail fashion and thus required addition of 4 cysteines. 
Residues 372 (Gly 372) and 373 (Asn 373) were identified as the head side spots for 
cysteine insertion. Residues 418 (Tyr 418) and 419 (Asn 419) were identified as the 
optimal tail side spots. This insertion of 4 cysteine residues on head-tail configuration 
ensures 2 FlAsH interactions as shown in Figure 5.4. On the trimeric protein subunit, 
residues 156 (Asp 156) and 157 (Asp 157) as well as 179 (Ile 179) and 180 (Ser 180) 
were identified as optimal for cysteine insertion. This ensures 2 FlAsH binding sites 







Figure 5.4: Illustration showing head-tail assembly of the dimer and cysteine 
insertions (a) No fluorescence: The absence of bipartite cysteine pairs during head-
tail dimerization would have no FlAsH binding. (b) 4 cysteines were engineered on 




The distance between the cysteine residues is crucial in terms of avoiding unintended 
binding false positives. FlAsH-EDT 2 recognizes proximally located bipartite cysteine 
pairs and emits a fluorescent signal. If the cysteines on one subunit were placed in 
close proximity, this would result in unintended flash binding (false positives). 
Initially, the two cysteine pairs on the dimer were separated by 10.6 Angstroms (Å). 
This was feared to result in a false validation. The distance between the two pairs was 
increased to 16 Å by inserting amino acids with minimal influence on the total 
structure (Figure 5.5). Similarly, it was ensured that the cysteine pairs on the trimeric 






Figure 5.5: Illustration explaining the importance of distance between the bipartite 
cysteine pairs.  (a) FlAsH-EDT recognising cysteine residues on the same subunit due 
to close proximity. (b) FlAsH-EDT recognising the bipartite cysteine pairs on the 





5.4.1.2 In silico validation of cage bio-assembly and functioning of inserted 
cysteines 
However, after intensive assembly modelling, it was discovered that incorporated 
cysteines were not presented on the external surface and were folding into the concave 






Figure 5.6: Protein cage assembly has been divided in half to show the internal (top 




The cysteine residues were redesigned, and multiple 3D models were generated to 
ensure the improved cysteine placement on the external curvature. On the dimeric 
subunit, residues 358 (Leu) and 359 (Gln) as well as 364 (Arg) and 365 (Phe) were 
replaced with cysteines. On the trimeric subunit residues 158 (Tyr) and 159 (Ala) as 
well as 181 (Glu) and (Glu) were replaced with cysteines. Following cysteine 
insertion, all proteins were remodelled using both I-Tasser and Rosetta. The 3D 
structures were visualised using Chimera to ensure proper bio-assembly. RMSD 
scores were calculated to inform on deviations from the original unmodified protein 






Figure 5.7: 3D models of dimer, trimeric and MegaMonomer subunits.  (a) The 
dimer subunits in assembly, showing the inserted cysteines (in red) at their binding 
interface. (b) Showing cysteine insertion (red) on a single dimeric protein subunit. (c) 
Trimeric protein with cysteine insertions superimposed on the unmodified protein. (d) 
MegaMonomer with cysteine inserted dimeric (blue) and trimeric (orange) subunits 
connected with a rigid helical linker (red). (e) RMSD of atomic distances of the 
MegaMonomer with cysteine insertion superimposed on the MegaMonomer without 
cysteine insertions.  
 
5.4.1.3 In silico validation of integrity of the modelled protein structures 
Ramachandran plots were generated for all protein constructs to theoretically validate 
the folding integrity. It was observed that 90 % of all amino acid residues in all three 
proteins fall in the most energetically favourable region and a maximum of 0.5 % in 
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the disallowed region. Table 5.4 summarises the Ramachandran plot scores for all 
three protein constructs. 
The Ramachandran plot for the MegaMonomer is shown in Figure 5.8. The 
computational models and evaluation provided sufficient confidence in the final 
















Dimer (1AA7) 90.4 % 9.6 % 0.0 % 
Trimer 
(1BRO) 
89.6 % 9.6 % 0.0 % 
Protein cage 90.3 % 9.2 % 0.5 % 






Figure 5.8: Ramachandran plot generated for MegaMonomer. The red, yellow and 
light yellow regions represent the favoured, allowed and disallowed regions 
respectively. Black dots represent the amino acid residues. The ψ (Psi) and φ (Phi) 




5.4.1.4 F2F plots to visualise overall performance 
F2F plots, as discussed in Chapter 3, were generated to have a holistic look on the 
overall performance of each designed construct. Solvent accessibility of the active 
sites (cysteine residues), PI, Grand hydrophobicity average, Instability index and 
Ramachandran Score (RC score) were used as plot axes. OP score was calculated as 





Figure 5.9: F2F plots for the dimer, trimer, and cage monomers. (a) F2F plot for 
trimer monomer, (b) F2F plot for dimer monomer (c) Plot for cage monomer 
(MegaMonomer). Lower OP score indicates high agreement between the designed 
construct parameters and desired in silico parameters. Trimer monomer showed the 
highest OP score and was predicted to perform the best. The dimer scored the highest 




5.4.2 Wet-lab experimentation 
5.4.2.1 Validating protein production 
 
Post-transformation, bacterial subcultures were induced for protein expression, using 
two different concentrations of IPTG (1 mM and 0.5 mM). Cells were harvested and 
the total protein concentration was determined using Bradford Assay. The 
concentrations of all protein samples were normalised to 5 μg/µl. A Western blot was 
carried out to validate and quantify the proteins of interest. FLAG-BAP was used as a 





Figure 5.10: Western blot validating protein production. Lanes 1,3 and 5 contain the 
proteins induced with 1mM IPTG and lanes 2, 4 and 6 contain the proteins induced 
with 0.5 mM IPTG. The 4 lanes on the extreme right show FLAG-BAP standards in 




5.4.2.2 Self-assembly verification strategy 
To validate the FlAsH-EDT2 binding mediated oligomerisation, a series of 
fluorescence assays were carried out in controlled in vitro conditions. In all the assays, 
a small stable protein (GLuc) with an engineered FlAsH-EDT2 binding tetra-cysteine 
motif (CC-PG-CC) was designed and used as a positive control for FlAsH-EDT2 
binding upon producing in E. coli in parallel with the test proteins. The rationale of 





Figure 5.11: Wet-lab strategy for confirming self-assembly. The positive control 
protein has a tetra-cysteine tag that binds to FlAsH-EDT and emits fluorescence 
independent of binding. The test proteins interface engineered bipartite cysteines and 
their fluorescence is self-assembly dependent. WT cells with no modification were 





5.4.2.3 Whole-cell FlAsH-EDT2 based fluorescence assays confirming 
oligomerisation 
Whole-cell fluorescence assays were carried out to validate self-assembly. All the 
bacterial cultures were maintained at 0.3 OD before harvesting for the assays. Intense 
care was taken to remove unintended autofluorescence. Figure 5.12 shows the 
outcome of the fluorescence-based FlAsH-EDT2 binding assays. As expected, the 
control protein generated the maximum fluorescence and the negative control had a 
minimum fluorescent signal. When compared with negative control, a two-fold 
increase in fluorescence was observed in the dimeric protein assembly, and a four-fold 
increase was observed in the trimeric assembly and the cage assembly. This provided 
a clear indication of protein-protein interactions and the response of the FlAsH-EDT2 
towards proximally placed bi-partite cysteines. The graphs representing the data in 







Figure 5.12: Confirmation of oligomerisation using FLaSH-EDT binding. Equal 
quantities of bacterial cells were harvested simultaneously and subjected to FLaSH-
EDT assay. (a) Fluorescence in signal to noise ratios. Cells without any modification 
were used as background noise. All samples were prepared in triplicate. All proteins 
with engineered bi-partite cysteines produced higher fluorescence than the negative 
control. (b) Percent fluorescence output was normalized to the positive control (GLuc 
with tetracysteine tag). The cage assembly produced a signal close to 48 % of the 
positive control, while the trimer and dimer assemblies produced 46 % and 21 % of 





Initially, the cage assembly was expected to produce higher fluorescence than the 
dimer and trimer assemblies. However, observing the data in Figure 5.12, this was not 
the case. In order to account for fluorescence per molecule, the data from Figure 5.12 
was used to calculate the relative fluorescence units per FlAsH binding site on each 






Figure 5.13: Relative fluorescence units per FlAsH binding site. All engineered 
proteins were expected to mediate similar fluorescence per FlAsH binding site. 
However, this was not observed in experimental validation. The Trimer and the cage 
assemblies produced similar (p=0.02) magnitude of fluorescence signal, but the dimer 





The current work utilised computational modelling and design approaches to engineer 
bipartite cysteines into the interface of the self-assembling proteins. Although the 
concept of using FlAsH-EDT to confirm protein-protein interaction or self-assembly 
has been done before, all such methods used bi-partite cysteines as a peptide tag at the 
N or C terminus of the protein. Although peptide tags are a validated as good reporters, 
complicated assemblies such as protein cages require proper exposure of the cysteines 
on the surface, at all stages of the self-assembly. The strategy used in this work, 
provides the design advantage of choosing the positioning of the cysteines. This is 
highly useful to eliminate false positive reporting due to proximally close non-
assembly conformations.     
Multiple iterations of In silico redesigning was performed using Rosetta to ensure 
structural stability and right conformational positioning of the cysteines. The data 
provided a clear indication that FlAsH-mediated fluorescence could be successfully 
deployed to monitor protein-protein interactions. As designed, the FlAsH biarsenical 
complex was able to validate the self-assembly in all three test proteins.  
Although the protein-protein interactions were confirmed, full validation of self-
assembly of complex structures poses further challenges. It was observed that the 
dimeric protein (M1 matrix protein of influenza virus) was produced in significantly 
lower quantities when compared with the other proteins in the wet-lab studies which 
also affected the cage MegaMonomers production. This could be due to M1 viral 
capsid protein resulting in protein aggregation as mentioned in previous studies [28]. 
The F2F plot for the dimeric protein also predicted a low performance. The ability of 
the cages to assemble into intermediate oligomers is one of such complications. It is 
also important to outline that the sample sources (cell lysates vs whole cells), cell 
concentrations (OD before harvesting) and buffer conditions would be expected to 
have significant influences on the study outcomes. The fluorescence assays were 
initially conducted on clarified cell lysates. However, this type of assay resulted in 
high background noise. Using whole-cells provided the scope to wash the unbound 
FlAsH-EDT by light centrifugation. FlAsH-EDT complex also has a tendency to 
recognise natural cysteine motifs presented on natural cellular proteins and resulting 
in non-specific binding. To avoid the non-specific FlAsH-EDT binding, the samples 
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were incubated with FlAsH buffer that contains 2ME and EDT which improved the 
selectivity of the FlAsH-EDT complex [29]. With stringent experimental conditions 
(such as with the addition of competing thiols) it was clearly shown that FlAsH 
binding could be improved with enhanced signal intensities. The mathematical 
approach to represent data in terms of fluorescence per FlAsH binding site did not 
reflect the expected results. The variations in the wet lab assays demand further 
experimental validation to confirm the oligomerisation states.  
However, further protein denaturing experiments are required to confirm the 
oligomerisation dependence of FlAsH-EDT2 based fluorescence. Techniques such as 
size exclusion chromatography (SEC) can be deployed to confirm the oligomerisation 
states. Additionally, a Cryo-EM image would solidify the evidence of cage assembly. 
Also, further experiments are needed to test the release kinetics of the cage. The results 
from this work are proof-of-concept to validate the functioning of the engineered bi-
partite cysteines and the imaging concept using FlAsH-EDT2. Without such further 
validation, the data on the current synthetic cage are insufficient for translation into a 
full application. 
With the increasing market for protein-based products, most academic and industrial 
settings would rely on monitoring proteins for their quality, interactions and stability. 
The concept of engineering bipartite cysteine residues, introduced in this work, is a 
proof-of-concept and building platform with an immense potential in biomedical 
technology. In the future, with the expanding interest in de novo protein design, this 
approach would benefit the visualisation of combinatorial assembly of various protein 
structures. This could be used to monitor various enzymatic and biochemical 
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Chapter 6  
Development and validation of a novel miniaturised optical imaging 
device 
 
A version of this chapter has been published as  
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Background  Current optical devices to monitor biological phenomena such as 
bacterial growth and biofluorescence are bulky, expensive and remain benchtop-
based. These factors can prevent real-time measurements in several cases, such as 
where biological processes are occurring in shaking incubators. Technologies such as 
miniaturised electronics, smartphone apps and 3D printing provide a rapid and low-
cost platform to design, build and test hardware and software for such biological 
processes.  
Aims  The aim of this work was to utilise enabling technology such as 3D 
printing, miniaturisation and smartphone-assisted electronics to provide a deployable 
solution towards continuous monitoring of bacterial growth.  
Methods  A handheld fitness tracker-based device (ODX) was developed for this 
purpose. Multiple protypes of designed hardware were used to optimise the form and 
functioning of the device. The final device was calibrated and tested using 3 different 
bacterial genera. The accuracy and reliability were compared with a benchtop 
spectrophotometer. A basic web-based app builder tool was used to build a smart-
phone app to record the data from the device.  
Results  The data from the growth curves validated the functioning of ODX. 
The accuracy tests carried out while calibrating the device proved ODX as accurate as 
a standard benchtop spectrophotometer. With smartphone-aided wireless data logging 
and other advantages such as portability and the ability to be taken into shaking 






6.2.1 Designing and deployability in synthetic biology 
With the advent of synthetic biology and de novo design, protein-based systems stand 
to dominate the commercial landscape of life sciences. Proteins find their applications 
in food-based industries, materials technology, and medicine and healthcare. This 
versatility of protein-based applications promises an increasing potential for 
commercialisation. This potential for commercialisation is complemented by recent 
advances in synthetic biology. Cheap DNA synthesis and sequencing, recombinant 
technology, computational tools, miniaturised electronics, automation and robotics 
have driven synthetic biology into a golden era. Modern synthetic biology highlights 
the importance of multidisciplinary approaches in designing biological solutions and 
aims to accelerate the pace of biological research by integrating various scientific 
disciplines [1]. Commercial viability requires transforming a scientific outcome into 
a deployable product. For example, a protein based diagnostic tool would additionally 
require an appropriate hardware for testing and a software to analyse and report the 
results. Technologies such as miniaturised electronics, smartphone apps and 3D 
printing provide a platform bed to design and test multiple variations of the product 
until its final form. 
 
6.2.2 Fitness tracker-based handheld devices for bacterial growth monitoring. 
Bacteria are present a commercially viable, cheap and easily scalable platform for 
protein expression [2]. For centuries, food processing and fermentation industries have 
driven the commercial markets of bacterial based products. The advent of recombinant 
technology paved the way for various engineered enzymes and novel protein-based 
therapeutics [3-5]. In all those mentioned above, clinical, scientific, and commercial 
settings, monitoring of the population, and growth kinetics of bacteria plays a crucial 
role [6]. Each species and strain of bacterium has unique growth kinetics [7]. These 
growth kinetics depend on various parameters such as oxygen availability, 
temperature, medium in which the bacteria are grown, pH, culture vessel, the volume 
of the culture etc. Working with these microorganisms typically requires continuous 
monitoring of growth patterns. In many cases, microbiologists monitor the microbial 
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growth regularly to ensure that the population does not exceed pre-set thresholds or to 
maintain the population at a particular level.  
Traditionally, several methods such as plate counting [8], direct counting [9], 
biomass measurement [9, 10], and light scattering have been used to measure bacterial 
growth. At present, optical density measurement based on the scattering of light from 
individual bacterial cells remains the gold standard. While the last few years have seen 
tremendous evolution of spectrophotometers, most of these devices are costly, bulky 
and remain benchtop based and so cannot be taken inside the incubator for real-time 
monitoring of OD measurements [11]. Furthermore, the usage of these instruments 
requires significant user interaction with the analyte and lack both versatility and 
flexibility due to their large form factor. These spectrophotometers also come with 
penalty of high labour costs and introduce contamination risks. 
Recent advances in electronic miniaturization have paved the way for various 
types of wrist-worn low-cost fitness trackers [12]. These commercially available 
fitness trackers typically track, monitor and analyse various activities such as physical 
movement, sleep, and heartbeat rate, facilitated by various sensors such as an 
accelerometer, heart rate monitor, ECG, GPS etc. The output of these sensors is 
processed and stored by a small but powerful microprocessor. Fitness trackers transmit 
the result of the activities directly to the built-in OLED screen as well as to 
smartphones via Bluetooth. Despite having many sophisticated sensors, a powerful 
microprocessor, and highly miniaturized design, these fitness trackers are priced as 
low as $10 on the consumer market. Of all the sensors in fitness trackers, the optical 
heart rate sensor is particularly interesting [13]. The heart rate sensor consists of LEDs, 
one or more photodiodes, the essential components required of an 
OD/colorimetric/fluorescence monitor. Modifying these cheap fitness trackers using 
miniature electronics and 3D printing technology could provide handheld OD and 
fluorescence monitoring solutions with several advantages and added benefits over the 
existing benchtop devices. Monitoring bacterial growth and protein expression stand 
to benefit immensely from miniaturised handheld optical devices.  
Considering the broad need for continuous remote bacterial growth 
monitoring, a fitness tracker-based handheld device, ODX, was developed to monitor 
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continuous bacterial growth (Figure 6.1). Leveraging the capability of ODX, its 
potential to measure fluorescence is also described.  
 
 
Figure 6.1: A schematic comparing the traditional method to the ODX device-based 
method for continuous optical bacterial growth monitoring. (a) The tube containing 
appropriate culture medium inoculated with bacterial cells. Traditional (b) Bacterial 
cultures in a shaking incubator (c) Laminar airflow chamber (all the biological 
sampling is done inside a laminar airflow chamber to reduce the potential risk of 
contamination) (d) Culture sample collected in a cuvette and OD measured using a 
commercial benchtop spectrophotometer. ODX (e) The sample is inserted into the 
ODX device and placed in a shaking incubator. (f) Basic components of ODX. (g) 





6.3 MATERIALS AND METHODS 
Hardware modifications were assisted by colleagues; Dr. Ganga Chinna Rao 
Devarapu and Uday Gowda in the Cork Institute of Technology. 
 
6.3.1 Optical and mechanical design of ODX device and choice of materials 
The ODX hardware consists of the following parts: 1. A generic fitness tracker 2. The 
3D printed enclosure 3. An orange LED. 4. A voltage regulator and a current regulator. 
 
6.3.2 Fitness tracker 
An ID107HR branded (Shenzhen DO Intelligent Technology Ltd) fitness tracker was 
chosen for the work presented in this article as it is inexpensive ($10 to $25) and 
widely available through online retailers. More importantly, it contains an nRF51822 
microprocessor from Nordic Semiconductors Ltd (Figure 6.2a), which has well-






Figure 6.2 The internal circuitry of the ID107HR fitness tracker. (a) Rear view of 
the circuit board showing SWD programming connections to upload the firmware into 
the fitness tracker (b) Front view of the circuit board showing nRF51822 
microcontroller and OLED display. (c) Heart rate sensor consisting of visible and IR 
photodiodes. (d) The spectral response of the visible (blue line) and IR (red line) 
photodiodes of the heart rate sensor (Si1143) [22] in the ID107HR fitness sensor. The 





The heart rate sensor (Si1143, Silicon Labs Ltd) in the ID107HR fitness tracker has 
two photodiodes (Figure 6.2c): one to cover the visible spectral range and the other to 
cover the infrared (IR) spectral range as indicated with blue and red lines respectively 
in Figure 6.2d. Raw readings from both PDs can be accessed using the modified 
firmware. These two PDs provide two complementary measurements for each optical 
density measurement of bacteria, thus resulting in more accurate OD values than OD 
meter designs that have only a single PD. 
 
6.3.3 LED 
The optical density of bacteria is usually measured at a wavelength of 600 nm as most 
bacteria and growth media in which bacteria are incubated known to have negligible 
absorption at that wavelength [14]. Therefore, an orange colored LED (C503B-AAN-
CY0B0251, CREE) with peak emission at a wavelength of 596 nm was chosen as the 
light source for the ODX device as it has low power consumption, small size, low 





Figure 6.3 3D printed enclosure of ODX device (a) Front view showing the holding 
space for a culture tube (sample holder), (b) Rear view showing the groove for an 
orange LED. (c) Bottom view showing the space for LED controlling circuit. A one-








6.3.4 3D printed enclosure 
The enclosure for the ODX device was designed with an open source parametric CAD 
software (OpenSCAD version 2015.03-2). The CAD design of ODX has provisions 
for holding the fitness tracker, a culture tube (Figure 6.3a), an orange LED (Figure 
6.3b) and the additional circuitry powering the LED (Figure 6.3c). The CAD design 
of the ODX enclosure was fabricated using a 3D printer (Ultimaker 3) with black 
coloured Polylactic Acid (PLA) material. 
 
6.3.5 Smartphone app development 
An Android app was specifically developed using an open source platform (App 
Inventor) to transfer the data from the ODX device to a smartphone via Bluetooth. The 
app then processes the data and displays the OD on the screen. Moreover, the app 
displays the growth of bacteria graphically in terms of OD and saves the data in a text 
file inside the smartphone's internal memory for further analysis. However, the 
primary role of the app was to let the users create alerts informing them when a 
bacterial culture reaches the required growth stage. The working mechanism of the 
firmware and the app are shown schematically in Figure 6.4a and Figure 6.4b, 





Figure 6.4 Functional workflow of ODX device (a) Firmware (b) Smartphone app 





6.3.6 Bacterial culture 
E. coli Nissle was grown on Luria Broth agar plates and 25 ml inocula made in LB 
broth from single colonies, before shaking at 37 °C overnight. S. aureus (ATCC 
25923) was cultured on Trypsin soy broth (TSB) agar plates and 25 ml inocula made 
in TSB broth from single colonies, before shaking at 30 °C overnight. S. agalactiae 
was grown on Trypsin soy broth (TSB) agar plates and 25 ml inoculum made in TSB 
broth from single colonies. Bacteria were sub-cultured in 50 ml falcon tubes by adding 
100 µl overnight bacterial culture to 30 ml of fresh broth. For batch measurements, 
bacterial cultures were diluted, and OD readings given by ODX device were recorded. 
For continuous measurement, the falcon tube containing freshly inoculated broth was 
inserted into the ODX device. The measurements were logged into a text file, which 
was later used for optimizing the ODX app. In all the cases, OD was cross verified by 
a standard spectrophotometer (Eppendorf BioPhotometer) in biological and technical 
replicates. Continuous growth monitoring was performed by seeding the bacteria into 





6.4.1 Deploying ODX hardware 
6.4.1.1 Calibration of ODX device  
To convert the ODX device output into optical density values, it was necessary to 
determine the empirical relationship between the ‘Visible and IR’ photodiode values 
of the heart rate sensor and the OD values given by a benchtop spectrophotometer. For 
this purpose, ODX was calibrated using three bacterial samples. Overnight cultures of 
E. coli Bl21, S. aureus and S. agalactiae were diluted to five different concentrations. 
Each sample was measured using the ODX as well as a traditional benchtop 
spectrophotometer and these results are plotted in Figure 6.5. A logarithmic function 
is fitted to these data sets following the Beer-Lambert law [15]. The quality of fit (R2) 
obtained for the visible and IR photodiodes were above 0.9 for all the three bacterial 
solutions, indicating the excellent quality of fit and showing the accuracy of above 
96% (assuming that the benchtop spectrometer has minimal error). For each of the 






Figure 6.5 Response of the IR photodiode (blue dots, top x-axis) and Visible 
photodiode (orange dots, bottom x-axis) for different optical density solutions (y-
axis). ODX was calibrated using three different bacterial strains (a) Escherichia coli 
Nissle, (b) Streptococcus agalactiae and (c) Staphylococcus aureus. The respective 





Bacteria Polynomial regression function R2 
Escherichia coli ODIR = -0.47 ln[IR] + 4.6351 0.9923 
ODVIS = -0.625 ln[Vis]+4.9436 0.9944 
Streptococcus 
agalactae 
ODIR = -0.344 ln[IR] +3.3413 0.9903 
ODVIS = -0.396 ln[Vis] + 3.1196 0.9865 
Staphylococcus 
aureus 
ODIR = -0.563 ln[IR] +5.4173 0.9878 
ODVIS = -0.674 ln[Vis] +5.2519 0.9737 
Table 6. 1 Calibration of the ODX using bacterial samples. Best fit functions and 





These logarithmic functions were used to obtain the optical density corresponding to 
each photodiode (ODIR and ODvis). The final optical density of a bacterial solution is 
obtained by calculating the weighted average of corresponding individual optical 
densities of IR and Vis photodiodes, i.e. OD = 0.5 (ODIR+ODvis). Accordingly, these 
logarithmic calibrating functions are programmed into the persistent memory of the 
fitness trackers microprocessor, so that raw readings of the photodiodes will directly 
output the OD values. 
 
6.4.2 Continuous bacterial growth monitoring 
The performance of the ODX device to continuously monitor bacterial growth was 
evaluated with three bacterial strains E. coli, S. aureus and S. agalactiae. Bacteria 
were inoculated in a 50ml tube containing growth media. The tube was inserted into 
the ODX device and placed in a shaking incubator. OD readings corresponding to the 
bacterial strains were collected wirelessly via Bluetooth-enabled smartphone and 
recorded using the ODX Android app. OD readings were measured every 8 sec and 
data extracted to plot the data representing the growth curves of the three bacterial 
strains. The measurement periods for these organisms were approximately 10h, 
allowing the collection of complete growth dynamics data. The results for batch-wise 
bacterial growth monitoring is shown in Figure 6.6. The three major growth phases of 






Figure 6.6 Growth curves of (a) Escherichia coli, (b) Staphylococcus aureus and (c) 
Streptococcus agalactiae obtained with the ODX device. In all cases, ODX was 
placed in a shaking incubator and the OD measurements (once every 8 sec) were 
recorded on a Bluetooth enabled smartphone. The resultant data are plotted after 
averaging the values for every 400 sec to avoid the slight variations in the OD values 




In all experiments, data from ODX were transmitted continuously to the ODX app via 
Bluetooth and throughout the process, it could be accessed in real-time. This real-time 
access to bacterial growth phase and optical density would be a highly valuable asset 
for fine-tuning the process efficiency in biotechnology industries. 
 
 
6.4.3 Adapting ODX for fluorescence 
As shown in Figure 6.2d, the photodiodes on the fitness tracker present in ODX have 
the capability to capture a wide range of emission spectra in the visible and IR 
wavelength regions. This allowed the adaptation of ODX into a fluorescence 
monitoring device. A second LED, whose emission wavelength matches the excitation 
wavelength of FlAsH-EDT2 (see Chapter 5), was engineered in ODX at the side 
interface to provide access to side illumination. An emission filter was placed in front 
of the diode (Figure 6.7). The software of the device was re-programmed to 
alternatively switch between the OD LED and Fluorescence LED, with an interval of 
8 sec. This ensures the capturing of two different photodiode outputs in parallel. Such 







Figure 6.7: Adapting ODX for fluorescence. (a) An additional groove for an emission 
filter was placed in front of the photodiodes. The LED for fluorescence excitation is 
placed on the side. (b) The build looks highly similar to ODX. An extra battery is 






The fluorescence capabilities were tested with Polystyrene Microspheres, 10 µm, 
yellow-green fluorescent (505/515) FluoSpheres™ (ThermoFisher Scientific 
F58836). Serial dilutions were made up to 10 different concentrations. All 
measurements were made in the dark. Although a noticeable photodiode response was 
lodged, the validation was unsuccessful as no linearity was observed in the data (data 
not shown). Further optimisation of excitation light intensities, integration times, and 






Monitoring of bacterial growth represents a staple process in every bacterial or 
biological engineering focused laboratory. Plotting the growth characteristics of 
various bacteria is important to harvest cells for protein production and to study the 
effects of various test substances on bacterial growth. The traditional method to 
measure OD and monitor bacterial growth is a time-consuming process, uses a huge 
amount of plastic consumables and adds risk of contamination. In this study, it has 
been shown that the ODX device has successfully overcome most of the problems and 
challenges posed by the traditional OD measuring methods. Bacteria are extensively 
used in research and industry. In most cases where bacteria are used as bio factories, 
the products (proteins, secondary metabolites etc.) are produced in the log phase of 
the bacterial growth. In such settings, the bacterial OD is maintained between 0.4 and 
0.8. For cloning DNA, bacterial OD of between 0.6 and 0.8 is preferred. ODX showed 
similar lower limit of detection to the benchtop spectrophotometer (as low as 0.01 OD, 
approx. 106 CFU). Thus, ODX maintains the same levels of quality standards as the 
benchtop spectrophotometers. 
By combining a generic fitness tracker and a smartphone-aided data reporting 
system, ODX forms a complete continuous bacterial monitoring system. In this study, 
ODX has been tested on three different bacterial strains and their growth was 
monitored continuously for over 10h. The resultant growth curves are shown in Figure 
6.6 resemble the typical bacterial growth curves [26]. ODX device presents several 
advantages over the existing commercial and DIY spectrophotometers. Since the ODX 
is ultra-portable, it could be used in various biological settings such as shaking 
incubators, anaerobic incubators or sterile laminar airflow chambers, thus eliminating 
the potential chances of contamination. ODX could also be used as a regular benchtop 
spectrophotometer as it can display the OD values on the OLED Screen without 
requiring a smartphone or a computer. ODX works with a range of standard sample 
containers. The current device was tested using a standard cuvette and a generic test-
tube (data not shown), thus eliminating the need for specific consumables.  
One of the key aspects of ODX is the availability of low-cost fitness trackers, 
that makes it affordable. Today, fitness trackers are available at a retail price of less 
than $10. These fitness trackers have all the electronic components required to make 
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OD meters. The same components, when bought individually, are the main 
contributors to the high costs of the currently proposed prototypes.  
Although the current work explores the potential of ODX primarily in an 
academic lab setting, the scope of ODX is not only limited to academic labs. Biotech 
industries such as the recombinant protein production industries, fermentation 
industries, dairy, and food-based industries, use turbidity and optical density 
monitoring for both batch and continuous quality monitoring. The portability and 
modularity to adopt in many settings expand the potential of ODX into any biotech 
industry setting. The ability to continuously log the data with unmanned supervision 
(via Bluetooth) reduces the risk of data fraud and data loss. This data log file could 
later be used for retrospective inspections [27]. Using wireless Bluetooth based 
systems avoids sophisticated wiring systems and decreases physical maintenance costs 
in the industry. OD methods are also widely used in clinical labs and hospitals for 
various blood, urine, and other body fluid analyses [28], [29]. The ODX could be 
deployed as an NPD (Near patient diagnostics) which reduces the burden on personnel 
on the health sector. The data logging system could form a very helpful feature for 
patients who require regular monitoring of body samples. This eliminates the manual 
errors in clinics where analyses are still done by physical examination by a staff 
member.  
In this work, the ability of ODX to continuously monitor the bacterial growth 
is shown, this is not possible with the current benchtop spectrophotometers. With all 
the features such as portability, versatility and the customisability ODX can be a 
valuable tool for monitoring bacteria in a wide range of academic and industrial 
settings. Continuous fluorescence monitoring capabilities were added to ODX with 
the aim of aiding confirmation of self-assembly of test constructs in Chapter 5. It was 
important to measure the bacterial growth continuously to validate the instrument as 
well as to provide a baseline for reference. This however, proved unsuccessful. In 
future, further hardware optimisation will be made to bring fluorescence features to 
ODX. This addition of fluorescence capability to such a handheld device would 





This study explores the scope of introducing miniaturised optical devices for 
biological experiments. Handheld devices such as ODX, bring deployability and 
reduce reliance on high-cost, bulky lab equipment. In this work, the end goal of 
continuous monitoring of bacterial growth was facilitated through various 
interdisciplinary resources. Enabling technology such as 3D printing and 
miniaturisation have provided the ease of design-model-build-test of multiple 
hardware and software prototypes. Modern day biomedical science demands novel 
concepts with deployable technology to assist their translation into user-based settings. 
The approach taken in this chapter uses principles of electronics, material design, wet-
lab assays and optics, working in tandem to deliver on the holistic goal.  
This approach stands as a unique example to demonstrate a strategy that would 
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DISCUSSION AND FUTURE PROSPECTS 
The work demonstrated in this thesis provides a proof-of-concept of in silico-aided 
design-model-build-test strategies for synthetic proteins. Various computational tools 
were used to ensure proper functioning of the subparts of all the synthetic proteins. 
Such a computationally informed design strategy would empower wet-lab biologist 
with prediction capabilities. 100s of different test variants of each synthetic protein 
were designed and modelled. Data from computational tools was used to screen for 
potential best performers. This process is analogous to high throughput screening that 
is observed in wet-lab drug design. However, the in silico screening only takes a 
fraction of the time to test the constructs in the wet-lab. The design and modelling 
process in this thesis heavily relied on computational tools. However, it must be noted 
that the accuracy of each computational tool is subjective to each protein. Predictions 
of synthetic proteins that resemble close similarity to naturally existing proteins have 
higher confidence levels and accuracy. Community-wide, worldwide studies such as 
CASP (Critical Assessment of protein Structure Prediction), CAPRI (Critical 
Assessment of PRediction of Interactions) and CAFA (Critical Assessment of 
Functional Annotation), organise regular blinded challenges to compare the 
performance of various computational tools for proteins [1-3]. With artificial 
intelligence, neural networks, deep learning and increased computational power, the 
road ahead is promising. The strategy presented here will grow in accuracy as the 
individual tools get updated.  
 
Development of targeted synthetic protein specific for S. aureus. Chapter 2 aimed to 
target ClfA of S. aureus. The basic functioning of the synthetic protein was validated 
using wet lab luminescence assays. Based on wet-lab data, the best performer was 
identified. The S1 test construct clearly stood as the best performer amongst all other 
test construct variants. With the encouraging results observed in the dose response 
assays, S1 was identified as a candidate worthy of examining in a future in vivo setting. 
Previous literature on the Nanoluc system indicated higher brightness and prolonged 
half-life, when compared to Gluc. Hence the Gluc was replaced with Nanoluc, to 
increase the signal intensity. This proved to be helpful later in Chapter 4. The 
technology developed would benefit from future, further validation work involving 
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FACS using anti-Flag fluorescent antibody and Western blottting to validate protein 
sizes, integrity and concentration.  
 
The in silico myriad problem and F2F bridge. As discussed in Chapter 2, the design 
parameter metrics define the quality of the individual parameter in the design and 
present an overwhelming amount and variety of data which are practically impossible 
to comprehend. Chapter 3 brings in mathematical concepts of machine learning to help 
predict the combined effect of the design parameters on the overall performance of a 
synthetic protein. F2F bridge is a novel way to visualize and score the overall 
performance of a test sequence. F2F bridge is a very useful tool for informed protein 
design, and may be deployed for low throughput design or high throughput screening. 
In a low throughput setting, the F2F plot would play a pivotal role in highlighting the 
‘pitfalls and merits’ of the design corresponding to a test sequence. The design could 
then be improved and F2F plot could be regenerated until satisfactory design is 
obtained. In a high throughput scenario, multiple designs of test sequences for an 
overall function are scored and ranked by F2F bridge.  
 Using machine learning approaches such as Lasso regression and the 
Random Forest regression tree models, F2F showed promising prospects for 
predicting the overall performance of a test sequence. The workflow and 
implementation of the prediction model is straightforward computationally compared 
with wet-lab experimentation. Synthesis/expression, functional assays and quality 
assessments of proteins is time consuming and is capital intensive. This results in a 
small size of dedicated datasets. Using datasets from multiple sources is also 
challenging due to the vast variability in wet-lab experimentation. Although this seems 
as a big challenge, recent advances in synthetic biology provide an inspiring platform 
for high throughput synthesis and testing of multiple proteins. Future work on F2F 
would involve training the mathematical model with larger datasets. Larger datasets 
would ensure increases in significance in prediction. The current model also relies on 
web servers and third party tools for assessing in silico parameters of a test sequence. 
This also means that the accuracy of the individual in silico parameter values depends 
on the corresponding tools developed by various sources. In a future version, the 
accuracy of every individual web server/tool would be taken into consideration to 
provide an overall confidence score on the predicted performance. This would prevent 
error-compounding. With little further adjustments in V.20, F2F bridge integrates in 
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the DMBT cycle and adds the ‘learn’ step by empowering the end-user (wet-lab 
biologist) with a holistic view on the overall performance of a protein. 
 
In vivo imaging using synthetic proteins. The technical know-how provided by F2F 
bridge and the results from Chapter 2, encouraged the building of synthetic protein for 
in vivo cell imaging. In silico design strategies from Chapter 2 were adapted to target 
MUC1. In vitro testing was carried out to validate secretion and functioning (binding 
and luminescence) of the all the synthetic proteins. Based on wet-lab validation and 
the ‘optimal performer’ logic, discussed in Chapter 4, M1 was chosen as the best 
candidate for in vivo imaging. The ability of the synthetic protein to circulate 
systemically throughout the body and localise to a specific target to produce an 
imageable luminescence signal acts as a proof-of-concept for in silico-aided synthetic 
protein design of targeted proteins for in vivo use (therapeutic, imaging etc). In vivo 
studies using systemically-administered M1-Gluc and S1-Gluc indicated localisation 
of this protein to target cells. In Chapter 2, a variant of S1 with Nanoluc was designed 
and tested in vitro. These assays didn’t show any noticeable in vitro advantage when 
Gluc was replaced with Nanoluc. However, in vivo, the NanolucS1 construct showed 
a significant improvement in signal intensity. In the future, similar to the synthetic 
proteins in Chapter 2, FACS using anti-Flag fluorescent antibody and Western blot 
could be performed to validate protein sizes, integrity and concentration. Furthermore, 
in vivo work would involve administering the mice with a non-targeting version of the 
proteins, which would have been beneficial to rule out the chances of accidental 
accumulation. Timepoint optimisation and pharmacokinetic studies of the protein 
would also benefit understanding the concepts such as bioavailability. 
 
In silico aided interface engineering of synthetic proteins. The capabilities of 
computational tools in protein design were exploited in both Chapter 2 and Chapter 4. 
In Chapter 5, in silico-aided protein engineering was used to engineer the protein 
interfaces to help visualise protein-protein interactions during self-assembly. A novel 
reporting strategy was introduced, by incorporating cysteine residues at the interaction 
interface of monomeric proteins of a self-assembling protein cage. The data from the 
wet-lab fluorescence assays provided a clear indication that FlAsH-mediated 
fluorescence could be successfully deployed to monitor protein-protein interactions. 
As designed, the FlAsH biarsenical complex was able to validate the self-assembly in 
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all three test proteins. However, further protein denaturing experiments are required 
to confirm the oligomerisation dependence of FlAsH-EDT2 based fluorescence. 
Techniques such as size exclusion chromatography (SEC) can be deployed to confirm 
the oligomerisation states. Also, further experiments are needed to test the release 
kinetics of the cage. The results from this work are proof-of-concept to validate the 
functioning of the engineered bi-partide cysteines and the reportitng concept using 
FlAsH-EDT2. Without such further validation, the data on the current synthetic cage 
are insufficient for translation into a full application. 
 
Handheld devices for biomedical applications In Chapter 6, the scope of introducing 
miniaturised optical devices for biological experiments was explored. A novel 
handheld device, ODX, for monitoring continuous bacterial growth, with prospects of 
measuring biofluorescence was developed. The device was tested using different 
bacteria and showed accuracy levels similar to a standard benchtop 
spectrophotometer. Handheld devices such as ODX, bring deployability and reduce 
reliance on high-cost, bulky lab equipment. In this work, the end goal of continuous 
monitoring of bacterial growth was facilitated through various interdisciplinary 
resources. Enabling technology such as 3D printing and miniaturisation have provided 
the ease of design-model-build-test of multiple hardware and software prototypes. 
Modern day biomedical science demands novel concepts with deployable technology 
to assist their translation into user-based settings. The approach taken in this chapter 
uses principles of electronics, material design, wet-lab assays and optics, working in 
tandem to deliver on the holistic goal. ODX stands as a unique example to demonstrate 
a strategy that would guide novel scientific concepts into deployable and 
commercially viable products. 
 
The goal of this thesis was to bridge interdisciplinary approaches in science to (i) aid 
laborious wet-lab experimentation and (ii) transform the novel biomedical concepts 
into deployable products. Chapters 2, 4 and 5 exploit the computational tools available 
today, to design and validate imaging strategies using synthetic proteins. Chapters 3 
and 6, on the other hand act as enabling technology that improves the ease and pace 
of the research. The marriage between these two goals has resulted in outcomes that 
have various future applications in biomedical science. 
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